<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00408408</url>
  </required_header>
  <id_info>
    <org_study_id>NSABP B-40</org_study_id>
    <secondary_id>NSABP B-40</secondary_id>
    <nct_id>NCT00408408</nct_id>
  </id_info>
  <brief_title>Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery</brief_title>
  <official_title>A Randomized Phase III Trial of Neoadjuvant Therapy in Patients With Palpable and Operable Breast Cancer Evaluating the Effect on Pathologic Complete Response (pCR) of Adding Capecitabine or Gemcitabine to Docetaxel When Administered Before AC With or Without Bevacizumab and Correlative Science Studies Attempting to Identify Predictors of High Likelihood for pCR With Each of the Regimens</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NSABP Foundation Inc</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>NSABP Foundation Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor
      cells, either by killing the cells or by stopping them from dividing. Giving more than one
      drug (combination chemotherapy) may kill more tumor cells. Monoclonal antibodies, such as
      bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells
      to grow and spread. Others find tumor cells and help kill them or carry tumor-killing
      substances to them. Bevacizumab may also stop the growth of breast cancer by blocking blood
      flow to the tumor. Giving chemotherapy and bevacizumab before surgery may make the tumor
      smaller and reduce the amount of normal tissue that needs to be removed. Giving bevacizumab
      after surgery may kill any tumor cells that remain after surgery. It is not yet known which
      chemotherapy regimen is more effective with or without bevacizumab in treating breast cancer.

      PURPOSE: This randomized phase III trial is studying six different chemotherapy regimens to
      compare how well they work with or without bevacizumab in treating women with stage I, stage
      II, or stage IIIA breast cancer that can be removed by surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Compare the efficacy of docetaxel followed by doxorubicin hydrocloride and
           cyclophosphamide (AC) vs docetaxel and capecitabine followed by AC vs docetaxel and
           gemcitabine hydrochloride followed by AC, with or without bevacizumab, in terms of an
           increase in the rate of pathologic complete response (pCR) in the breast, in women with
           palpable or operable breast cancer.

      Secondary

        -  Compare docetaxel/capecitabine with AC vs docetaxel/gemcitabine hydrochloride with AC vs
           docetaxel with AC, with or without bevacizumab, in terms of the rate of pCR in the
           breast and all post-therapy lymph nodes evaluated histologically (pCR breast and nodes).

        -  Determine whether the addition of bevacizumab to the docetaxel/anthracycline-based
           regimens (docetaxel with AC, docetaxel and capecitabine with AC, and docetaxel and
           gemcitabine hydrochloride with AC) will increase the rate of pCR of the breast and nodes
           compared to the same docetaxel/anthracycline-based regimens without bevacizumab in these
           patients.

        -  Determine whether the addition of capecitabine or gemcitabine hydrochloride to
           docetaxel, with or without bevacizumab, will increase the rate of clinical overall
           response (cOR) compared to docetaxel alone with or without bevacizumab in these
           patients.

        -  Determine whether the addition of bevacizumab to the docetaxel/anthracycline-based
           regimens will increase the rate of cOR compared to the same
           docetaxel/anthracycline-based regimens without bevacizumab in these patients.

        -  Determine whether the addition of capecitabine or gemcitabine hydrochloride to
           docetaxel, with or without bevacizumab, will increase the rate of clinical complete
           response (cCR) compared to docetaxel alone with or without bevacizumab in these
           patients.

        -  Determine whether the addition of bevacizumab to the docetaxel/anthracycline-based
           regimens (docetaxel with AC, docetaxel/capecitabine with AC, and docetaxel/gemcitabine
           hydrochloride with AC) will increase the rate of cCR compared to the same
           docetaxel/anthracycline-based regimens without bevacizumab in these patients.

        -  Identify gene expression profiles that can predict pCR in patients treated with the
           different sequential docetaxel/anthracycline-based regimens with or without bevacizumab.

        -  Identify gene expression profiles that can predict cOR in patients treated with
           docetaxel alone, docetaxel/capecitabine, or docetaxel/gemcitabine hydrochloride with or
           without bevacizumab.

        -  Determine the accuracy of an in vitro chemoresponse assay (ChemoFx®) as a predictor of
           pCR in patients treated with the different sequential docetaxel/anthracycline-based
           regimens without bevacizumab.

        -  Determine the accuracy of ChemoFx® as a predictor of cOR in patients treated with
           docetaxel alone, docetaxel/capecitabine, or docetaxel/gemcitabine hydrochloride without
           bevacizumab in these patients.

        -  Determine the impact of preoperative bevacizumab and sequential chemotherapy regimens
           and postoperative bevacizumab therapy on cardiac function in these patients.

        -  Determine the impact of bevacizumab on surgical complications in these patients.

        -  Determine the toxicity of the preoperative regimens and the toxicity of postoperative
           bevacizumab in these patients.

        -  Compare the docetaxel/anthracycline-based regimens with vs without bevacizumab, in terms
           of an increase in disease-free survival, of these patients.

      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to tumor
      size (2-4 cm vs &gt; 4 cm), nodal status (negative vs positive), hormone receptor status
      (estrogen receptor [ER]-positive and/or progesterone-receptor [PgR]-positive vs ER- and
      PgR-negative), and age (&lt; 50 years vs ≥ 50 years). Patients are randomized to 1 of 6
      treatment arms.

      Core needle biopsies are performed at baseline. Tumor tissue samples are also collected
      during definitive surgery. Samples are examined for gene expression and polymorphism by
      reverse transcriptase-polymerase chain reaction analysis and chemoresponse assay (ChemoFx®).

      After completion of study therapy, patients are followed periodically for 10 years.

      PROJECTED ACCRUAL: A total of 1,200 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathologic Complete Response (pCR) of the Primary Tumor in the Breast</measure>
    <time_frame>Time of surgery, on average 6 or 13 months</time_frame>
    <description>Percentage of patients absent of histologic evidence of invasive tumor cells in the surgical breast specimen.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>pCR in the Breast and Nodes</measure>
    <time_frame>Time of surgery, on average 6 or 13 months</time_frame>
    <description>Percentage of patients absent of histologic evidence of invasive tumor cells in the surgical breast specimen and axillary lymph nodes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Overall Response (cOR) Following Docetaxel Alone, Docetaxel/Capecitabine, and Docetaxel/Gemcitabine Hydrochloride, With or Without Bevacizumab, as Assessed by Physical Exam at the Completion of the Docetaxel-based Portion of Chemotherapy</measure>
    <time_frame>Assessed at cycle 5 of chemotherapy, on average at 15 weeks</time_frame>
    <description>Percentages of patients assessed as Clinical Complete Response or Clinical Partial Response according to RECIST.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Overall Response: cOR as Assessed by Physical Exam at the Completion of the Sequential Chemotherapy Regimens</measure>
    <time_frame>Three to four weeks after the last chemotherapy dose on average 6 or 13 months</time_frame>
    <description>The percentage of patients assessed by physical exam as Clinical Complete Response or Clinical Partial Response according to RECIST.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Complete Response (cCR) Following Docetaxel Alone, Docetaxel/Capecitabine, and Docetaxel/Gemcitabine Hydrochloride, With or Without Bevacizumab, as Assessed by Physical Exam at Completion of Therapy</measure>
    <time_frame>Assessed at cycle 5 of chemotherapy, on average at 15 weeks</time_frame>
    <description>Percentages of patients assessed as Clinical Complete Response or Clinical Partial Response according to RECIST.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Complete Resonse: cCR as Assessed by Physical Exam at the Completion of the Sequential Chemotherapy Regimens</measure>
    <time_frame>Three to four weeks after the last chemotherapy dose, on average at 6 or 13 months</time_frame>
    <description>The percentage of patients assessed by physical exam as Clinical Complete Response according to RECIST.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Cardiac Events</measure>
    <time_frame>After each cycle, 3-5 weeks postoperative, 9 and 12 months from study entry, every 6 month years 2-5, and annually years 6-10, for postoperative bevacizumab patients, every 6 weeks during postoperative therapy and at 18 months following study entry.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical Complication</measure>
    <time_frame>24 months after study entry</time_frame>
    <description>Number of patients with Grade 4 or above surgery-related toxicities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicities Including Events Other Than Congestive Heart Failure, of Chemotherapy Alone, Bevacizumab With Chemotherapy, and Bevacizumab Alone</measure>
    <time_frame>24 months after study entry</time_frame>
    <description>The number of patients who experienced Grade 1 or above Adverse Events. Referring to the Adverse Events tables for specifics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free Survival (DFS)</measure>
    <time_frame>Measured through 5 years after study enrollment</time_frame>
    <description>Percentage of patients free from local recurrence following mastectomy, local recurrence in the ipsilateral breast following lumpectomy, regional recurrence, distant recurrence, contralateral breast cancer, second primary cancer after 5 years.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">1206</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm 1A: Docetaxel then AC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive docetaxel IV on day 1 every 3 weeks for up to 4 cycles. Patients then receive AC IV every 3 weeks for up to 4 cycles. Patients then undergo surgery (lumpectomy or mastectomy).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 1B Docetaxel + Bev then AC + Bev</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive bevacizumab (bev) IV on day 1 and docetaxel every 3 weeks for up to 4 cycles. Patients then receive AC every 3 weeks for up to 4 cycles and 2 additional cycles of bevacizumab concurrent with the first 2 cycles of AC. Patients then undergo surgery as in Arm 1A. At least 4-6 weeks after surgery, patients receive adjuvant bevacizumab IV every 3 weeks for up to 10 cycles in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2A: Docetaxel + Capecitabine then AC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive docetaxel as in Arm 1A and oral capecitabine (cape) twice daily on days 1-14 every 3 weeks for up to 4 cycles. Patients then receive AC as in Arm 1A. Patients then undergo surgery as in Arm 1A.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2B: Docetaxel + Cape + Bev then AC + Bev</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive bevacizumab as in Arm 1B and docetaxel and capecitabine as in Arm III. Treatment repeats every 3 weeks for up to 4 cycles. Patients then receive AC every 3 weeks for up to 4 cycles and 2 additional cycles of bevacizumab concurrent with the first 2 cycles of AC. Patients then undergo surgery as in Arm 1B. At least 4-6 weeks after surgery, patients receive adjuvant bevacizumab as in Arm 1B.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3A: Docetaxel + Gem then AC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive docetaxel as in Arm 1A and gemcitabine hydrochloride IV on days 1 and 8 of each cycle every 3 weeks for up to 4 cycles. Patients then receive AC as in Arm 1A. Patients then undergo surgery as in Arm 1A.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3B: Docetaxel + Gem + Bev then AC + Bev</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive docetaxel as in Arm 1A, gemcitabine hydrochloride as in Arm 3A, and bevacizumab as in Arm 1B. Patients then receive AC every 3 weeks for up to 4 cycles and 2 additional cycles of bevacizumab concurrent with the first 2 cycles of AC. Patients then undergo surgery as in Arm 1A. At least 4-6 weeks after surgery, patients receive adjuvant bevacizumab as in Arm 1B.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <description>15 mg/kg IV</description>
    <arm_group_label>Arm 1B Docetaxel + Bev then AC + Bev</arm_group_label>
    <arm_group_label>Arm 2B: Docetaxel + Cape + Bev then AC + Bev</arm_group_label>
    <arm_group_label>Arm 3B: Docetaxel + Gem + Bev then AC + Bev</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
    <description>825 mg/m2 orally</description>
    <arm_group_label>Arm 2A: Docetaxel + Capecitabine then AC</arm_group_label>
    <arm_group_label>Arm 2B: Docetaxel + Cape + Bev then AC + Bev</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>600 mg/m2 IV</description>
    <arm_group_label>Arm 1A: Docetaxel then AC</arm_group_label>
    <arm_group_label>Arm 1B Docetaxel + Bev then AC + Bev</arm_group_label>
    <arm_group_label>Arm 2A: Docetaxel + Capecitabine then AC</arm_group_label>
    <arm_group_label>Arm 2B: Docetaxel + Cape + Bev then AC + Bev</arm_group_label>
    <arm_group_label>Arm 3A: Docetaxel + Gem then AC</arm_group_label>
    <arm_group_label>Arm 3B: Docetaxel + Gem + Bev then AC + Bev</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
    <description>100 mg/m2 IV</description>
    <arm_group_label>Arm 1A: Docetaxel then AC</arm_group_label>
    <arm_group_label>Arm 1B Docetaxel + Bev then AC + Bev</arm_group_label>
    <arm_group_label>Arm 2A: Docetaxel + Capecitabine then AC</arm_group_label>
    <arm_group_label>Arm 2B: Docetaxel + Cape + Bev then AC + Bev</arm_group_label>
    <arm_group_label>Arm 3A: Docetaxel + Gem then AC</arm_group_label>
    <arm_group_label>Arm 3B: Docetaxel + Gem + Bev then AC + Bev</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride (Adriamycin)</intervention_name>
    <description>60 mg/m2 IV</description>
    <arm_group_label>Arm 1A: Docetaxel then AC</arm_group_label>
    <arm_group_label>Arm 1B Docetaxel + Bev then AC + Bev</arm_group_label>
    <arm_group_label>Arm 2A: Docetaxel + Capecitabine then AC</arm_group_label>
    <arm_group_label>Arm 2B: Docetaxel + Cape + Bev then AC + Bev</arm_group_label>
    <arm_group_label>Arm 3A: Docetaxel + Gem then AC</arm_group_label>
    <arm_group_label>Arm 3B: Docetaxel + Gem + Bev then AC + Bev</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
    <description>1000 mg/m2 IV</description>
    <arm_group_label>Arm 3A: Docetaxel + Gem then AC</arm_group_label>
    <arm_group_label>Arm 3B: Docetaxel + Gem + Bev then AC + Bev</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient must have consented to participate and must have signed and dated an
             appropriate Institutional Review Board (IRB)-approved consent form that conforms to
             federal and institutional guidelines for the study treatment and submission of
             pre-entry core biopsy material for correlative studies.

          -  Patients must be female.

          -  Patients must be 18 years of age or older.

          -  Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of
             0 or 1.

          -  The diagnosis of invasive adenocarcinoma of the breast must have been made by core
             needle biopsy.

          -  The primary breast tumor must be palpable and measure greater than or equal to 2.0 cm
             on physical exam.

          -  All patients must have their left ventricular ejection fraction (LVEF) assessed by
             multigated acquisition (MUGA) scan or echocardiogram within 3 months prior to study
             entry. The LVEF must be greater than or equal to the lower limit of normal (LLN) for
             the cardiac imaging facility performing the study. Note: If the cardiac imaging
             facility cannot provide a LLN, use 50% as the LLN value.

             - Note: Since the pre-entry LVEF serves as the baseline for comparing subsequent LVEF
             assessments to determine if bevacizumab therapy can be continued, it is critical that
             this baseline study be an accurate assessment of the patient's LVEF. If the baseline
             LVEF is greater than 75%, the investigator should have the study reviewed for accuracy
             prior to study entry. Following study entry, the LVEF determination may be reviewed up
             until the time of the post-chemotherapy (preoperative) evaluation. Please note that if
             a more accurate value is obtained from the review of the baseline MUGA or
             echocardiogram, the correct value must be submitted to the NSABP before the
             post-chemotherapy (preoperative) MUGA or echocardiogram is performed or it cannot be
             used for managing postoperative bevacizumab.

          -  All patients must have an EKG within 3 months prior to study entry.

          -  At the time of randomization:

               -  Absolute neutrophil count (ANC) must be greater than or equal to 1200/mm3.

               -  Platelet count must be greater than or equal to 100,000/mm3.

               -  Hemoglobin must be greater than or equal to 10 g/dL.

               -  There must be evidence of adequate hepatic function by these criteria:

               -  Total bilirubin must be less than or equal to the ULN for the lab unless the
                  patient has a grade 1 bilirubin elevation (greater than ULN to 1.5 x ULN)
                  resulting from Gilbert's disease or similar syndrome due to slow conjugation of
                  bilirubin; and

               -  Alkaline phosphatase must be less than or equal 2.5 x ULN for the lab; and

               -  Aspartate Aminotransferase (AST) must be less than or equal to 1.5 x ULN for the
                  lab.

               -  Alkaline phosphatase and AST may not both be greater than the ULN. For example,
                  if the alkaline phosphatase is greater than the ULN but less than or equal 2.5 x
                  ULN, then the AST must be less than or equal the ULN. If the AST is greater than
                  the ULN but less than or equal 1.5 x ULN, then the alkaline phosphatase must be
                  less than or equal ULN.

          -  Patients with either skeletal pain or alkaline phosphatase that is greater than ULN
             but less than or equal 2.5 x ULN are eligible for inclusion in the study if bone scans
             do not demonstrate metastatic disease. Suspicious findings on bone scan must be
             confirmed as benign by x-ray, MRI, or biopsy.

          -  Patients with AST or alkaline phosphatase greater than ULN are eligible for inclusion
             in the study if liver imaging does not demonstrate metastatic disease and adequate
             bone marrow and liver function results as described above are met.

          -  The following criteria for evidence of adequate renal function must be met:

          -  Serum creatinine less than or equal ULN for the lab.

          -  Calculated creatinine clearance must be greater than 50 mL/min.

          -  Urine protein/urine creatinine (UPC) ratio must be less than 1.0.

          -  Patient must be able to swallow oral medications.

        Exclusion criteria:

          -  Tumor determined to be strongly human epidermal growth factor receptor 2
             (HER2)-positive by immunohistochemistry (3+) or by fluorescent in situ hybridization
             (positive for gene amplification).

          -  Excisional or incisional biopsy for this primary breast tumor.

          -  Surgical axillary staging procedure prior to study entry. Exceptions: 1) Fine Needle
             Aspiration (FNA) or core biopsy of an axillary node is permitted for any patient, and
             2) although not recommended, a pre-neoadjuvant therapy sentinel lymph node biopsy for
             patients with clinically negative axillary nodes is permitted.

          -  Tumors clinically staged as T4.

          -  Ipsilateral cN2b or cN3 disease. (Patients with cN1 or cN2a disease are eligible.)

          -  Definitive clinical or radiologic evidence of metastatic disease.

          -  Synchronous bilateral breast cancer (invasive or DCIS).

          -  Treatment including radiation therapy, chemotherapy, biotherapy, and/or hormonal
             therapy for the currently diagnosed breast cancer prior to study entry.

          -  Any sex hormonal therapy, e.g., birth control pills, ovarian hormonal replacement
             therapy, etc. (These patients are eligible if this therapy is discontinued prior to
             randomization.)

          -  Therapy with any hormonal agent such as raloxifene, tamoxifen, or other selective
             estrogen receptor modulator (SERM), either for osteoporosis or breast cancer
             prevention. (Patients are eligible only if these medications are discontinued prior to
             randomization.)

          -  Prior history of breast cancer, including DCIS. (Patients with a history of lobular
             carcinoma in situ [LCIS] are eligible.)

          -  Prior therapy with anthracyclines, taxanes, capecitabine, 5-FU (fluorouracil),
             gemcitabine, or bevacizumab for any malignancy.

          -  Other malignancies unless the patient is considered to be disease-free for 5 or more
             years prior to randomization and is deemed by her physician to be at low risk for
             recurrence. Patients with the following cancers are eligible if diagnosed and treated
             within the past 5 years: carcinoma in situ of the cervix, carcinoma in situ of the
             colon, melanoma in situ, and basal cell and squamous cell carcinoma of the skin.

          -  Cardiac disease that would preclude the use of anthracyclines. This includes:

               -  angina pectoris that requires the use of anti-anginal medication;

               -  history of documented congestive heart failure;

               -  serious cardiac arrhythmia requiring medication;

               -  severe conduction abnormality;

               -  valvular disease with documented cardiac function compromise; and

               -  uncontrolled hypertension defined as BP greater than 150/90 on antihypertensive
                  therapy. (Patients with hypertension that is well controlled on medication are
                  eligible.)

          -  History of myocardial infarction documented by elevated cardiac enzymes or persistent
             regional wall abnormalities on assessment of LV function.

          -  History of transient ischemic attack (TIA) or cerebrovascular accident (CVA).

          -  History of other arterial thrombotic event within 12 months before study entry.

          -  Symptomatic peripheral vascular disease.

          -  Any significant non-traumatic bleeding within 6 months before study entry.

          -  Serious or non-healing wound, skin ulcers, or incompletely healed bone fracture.

          -  Gastroduodenal ulcer(s) determined by endoscopy to be active.

          -  Invasive procedures defined as follows:

               -  Major surgical procedure, open biopsy, or significant traumatic injury within 28
                  days prior to planned start of study therapy. (Note: Placement of a vascular
                  access device is not considered a major surgical procedure.)

               -  Anticipation of need for major surgical procedures (other than the required
                  breast surgery) during the course of the study.

          -  Known bleeding diathesis or coagulopathy. (Patients on warfarin with an in-range
             international normalized ratio [INR] [usually between 2 and 3] are eligible.)

          -  Sensory/motor neuropathy greater than or equal grade 2, as defined by the NCI's Common
             Terminology Criteria for Adverse Events Version 3.0 (CTCAE v3.0).

          -  Other non-malignant systemic disease (cardiovascular, renal, hepatic, etc.) that would
             preclude treatment with any of the treatment regimens or would prevent required
             follow-up.

          -  Conditions that would prohibit administration of corticosteroids.

          -  History of severe hypersensitivity reaction to drugs formulated with polysorbate 80.

          -  Administration of any investigational agents within 30 days before study entry.

          -  Pregnancy or lactation at the time of proposed randomization.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Norman Wolmark, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NSABP Foundation Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arkansas Cancer Research Center at University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Bay Radiation Oncology Center</name>
      <address>
        <city>Castro Valley</city>
        <state>California</state>
        <zip>94546</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eden Medical Center</name>
      <address>
        <city>Castro Valley</city>
        <state>California</state>
        <zip>94546</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valley Medical Oncology Consultants - Castro Valley</name>
      <address>
        <city>Castro Valley</city>
        <state>California</state>
        <zip>94546</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente - Fremont</name>
      <address>
        <city>Fremont</city>
        <state>California</state>
        <zip>94538</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valley Medical Oncology</name>
      <address>
        <city>Fremont</city>
        <state>California</state>
        <zip>94538</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Associates</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Medical Center - Hayward</name>
      <address>
        <city>Hayward</city>
        <state>California</state>
        <zip>94545</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scripps Cancer Center - San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loma Linda University Cancer Institute at Loma Linda University Medical Center</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Contra Costa Regional Medical Center</name>
      <address>
        <city>Martinez</city>
        <state>California</state>
        <zip>94553-3156</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>El Camino Hospital Cancer Center</name>
      <address>
        <city>Mountain View</city>
        <state>California</state>
        <zip>94040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Highland General Hospital</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alta Bates Summit Medical Center - Summit Campus</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bay Area Breast Surgeons, Incorporated</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Bay Area Tumor Institute</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Larry G Strieff MD Medical Corporation</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tom K Lee, Incorporated</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Medical Center - Oakland</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph Hospital Regional Cancer Center - Orange</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Desert Regional Medical Center Comprehensive Cancer Center</name>
      <address>
        <city>Palm Springs</city>
        <state>California</state>
        <zip>92262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valley Care Medical Center</name>
      <address>
        <city>Pleasanton</city>
        <state>California</state>
        <zip>94588</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valley Medical Oncology Consultants - Pleasanton</name>
      <address>
        <city>Pleasanton</city>
        <state>California</state>
        <zip>94588</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Medical Center - Redwood City</name>
      <address>
        <city>Redwood City</city>
        <state>California</state>
        <zip>94063</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Medical Center - Richmond</name>
      <address>
        <city>Richmond</city>
        <state>California</state>
        <zip>94801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Medical Center - Roseville</name>
      <address>
        <city>Roseville</city>
        <state>California</state>
        <zip>95661</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Sacramento Kaiser-Permanente Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95823</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Medical Center - Sacramento</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95825</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Salinas Valley Memorial Hospital</name>
      <address>
        <city>Salinas</city>
        <state>California</state>
        <zip>93901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Medical Office -Vandever Medical Office</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Medical Center - San Francisco Geary Campus</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Medical Center - Santa Teresa</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Doctors Medical Center - San Pablo Campus</name>
      <address>
        <city>San Pablo</city>
        <state>California</state>
        <zip>94806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Foundation Hospital - San Rafael</name>
      <address>
        <city>San Rafael</city>
        <state>California</state>
        <zip>94903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Medical Center - Santa Clara Kiely Campus</name>
      <address>
        <city>Santa Clara</city>
        <state>California</state>
        <zip>95051</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Medical Center - Santa Rosa</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Medical Center - South San Francisco</name>
      <address>
        <city>South San Francisco</city>
        <state>California</state>
        <zip>94080</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Medical Facility - Stockton</name>
      <address>
        <city>Stockton</city>
        <state>California</state>
        <zip>95210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Medical Center - Vallejo</name>
      <address>
        <city>Vallejo</city>
        <state>California</state>
        <zip>94589</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Medical Center - Walnut Creek</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94596</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aurora Presbyterian Hospital</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boulder Community Hospital</name>
      <address>
        <city>Boulder</city>
        <state>Colorado</state>
        <zip>80301-9019</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Hospital Cancer Center - Colorado Springs</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penrose Cancer Center at Penrose Hospital</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80933</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Anthony Central Hospital</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente - Denver</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Porter Adventist Hospital</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Presbyterian - St. Luke's Medical Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph Hospital</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rose Medical Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Colorado Cancer Research Program</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80224-2522</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Mary's Regional Cancer Center at St. Mary's Hospital and Medical Center</name>
      <address>
        <city>Grand Junction</city>
        <state>Colorado</state>
        <zip>81502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Colorado Medical Center</name>
      <address>
        <city>Greeley</city>
        <state>Colorado</state>
        <zip>80631</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente - Lafayette</name>
      <address>
        <city>Lafayette</city>
        <state>Colorado</state>
        <zip>80026</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sky Ridge Medical Center</name>
      <address>
        <city>Lone Tree</city>
        <state>Colorado</state>
        <zip>80124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hope Cancer Care Center at Longmont United Hospital</name>
      <address>
        <city>Longmont</city>
        <state>Colorado</state>
        <zip>80501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McKee Medical Center</name>
      <address>
        <city>Loveland</city>
        <state>Colorado</state>
        <zip>80539</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Mary - Corwin Regional Medical Center</name>
      <address>
        <city>Pueblo</city>
        <state>Colorado</state>
        <zip>81004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Suburban Medical Center</name>
      <address>
        <city>Thornton</city>
        <state>Colorado</state>
        <zip>80229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Exempla Lutheran Medical Center</name>
      <address>
        <city>Wheat Ridge</city>
        <state>Colorado</state>
        <zip>80033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center</name>
      <address>
        <city>Farmington</city>
        <state>Connecticut</state>
        <zip>06360-2875</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helen and Harry Gray Cancer Center at Hartford Hospital</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06102-5037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Connecticut Hematology and Oncology Associates</name>
      <address>
        <city>Norwich</city>
        <state>Connecticut</state>
        <zip>06360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tunnell Cancer Center at Beebe Medical Center</name>
      <address>
        <city>Lewes</city>
        <state>Delaware</state>
        <zip>19958</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Christiana Care Health Services</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sibley Memorial Hospital</name>
      <address>
        <city>Washington, D.C.</city>
        <state>District of Columbia</state>
        <zip>20016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herbert D. Kerman Regional Oncology Center - Daytona Beach</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michael and Dianne Bienes Comprehensive Cancer Center at Holy Cross Hospital</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Broward General Medical Center Cancer Center</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Cancer Institute - Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ella Milbank Foshay Cancer Center at Jupiter Medical Center</name>
      <address>
        <city>Jupiter</city>
        <state>Florida</state>
        <zip>33458</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Mount Sinai Medical Center</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Hospital Cancer Institute at Florida Hospital Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803-1273</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M.D. Anderson Cancer Center at Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phoebe Cancer Center at Phoebe Putney Memorial Hospital</name>
      <address>
        <city>Albany</city>
        <state>Georgia</state>
        <zip>31701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northeast Georgia Medical Center</name>
      <address>
        <city>Gainesville</city>
        <state>Georgia</state>
        <zip>30501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Curtis and Elizabeth Anderson Cancer Institute at Memorial Health University Medical Center</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31403-3089</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nancy N. and J. C. Lewis Cancer and Research Pavilion at St. Joseph's/Candler</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kapiolani Medical Center at Pali Momi</name>
      <address>
        <city>'Aiea</city>
        <state>Hawaii</state>
        <zip>96701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Research Center of Hawaii</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OnCare Hawaii, Incorporated - Lusitana</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen's Cancer Institute at Queen's Medical Center</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Straub Clinic and Hospital, Incorporated</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hawaii Medical Center - East</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OnCare Hawaii, Incorporated - Kuakini</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente - Moanalua Medical Center and Clinic</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96819</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kapiolani Medical Center for Women and Children</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96826</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maui Memorial Medical Center</name>
      <address>
        <city>Wailuku</city>
        <state>Hawaii</state>
        <zip>96793</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Cancer Institute - Maui</name>
      <address>
        <city>Wailuku</city>
        <state>Hawaii</state>
        <zip>96793</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kootenai Cancer Center - Coeur d'Alene</name>
      <address>
        <city>Coeur d'Alene</city>
        <state>Idaho</state>
        <zip>83814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Anthony's Hospital at Saint Anthony's Health Center</name>
      <address>
        <city>Alton</city>
        <state>Illinois</state>
        <zip>62002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Illinois CancerCare - Bloomington</name>
      <address>
        <city>Bloomington</city>
        <state>Illinois</state>
        <zip>61701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph Medical Center</name>
      <address>
        <city>Bloomington</city>
        <state>Illinois</state>
        <zip>61701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Graham Hospital</name>
      <address>
        <city>Canton</city>
        <state>Illinois</state>
        <zip>61520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Illinois CancerCare - Canton</name>
      <address>
        <city>Canton</city>
        <state>Illinois</state>
        <zip>61520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Illinois CancerCare - Carthage</name>
      <address>
        <city>Carthage</city>
        <state>Illinois</state>
        <zip>62321</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Hospital</name>
      <address>
        <city>Carthage</city>
        <state>Illinois</state>
        <zip>62321</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John H. Stroger, Jr. Hospital of Cook County</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612-3785</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Decatur Memorial Hospital Cancer Care Institute</name>
      <address>
        <city>Decatur</city>
        <state>Illinois</state>
        <zip>62526</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alexian Brothers Radiation Oncology</name>
      <address>
        <city>Elk Grove Village</city>
        <state>Illinois</state>
        <zip>60007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eureka Community Hospital</name>
      <address>
        <city>Eureka</city>
        <state>Illinois</state>
        <zip>61530</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Illinois CancerCare - Eureka</name>
      <address>
        <city>Eureka</city>
        <state>Illinois</state>
        <zip>61530</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Francis Hospital</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galesburg Clinic, PC</name>
      <address>
        <city>Galesburg</city>
        <state>Illinois</state>
        <zip>61401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galesburg Cottage Hospital</name>
      <address>
        <city>Galesburg</city>
        <state>Illinois</state>
        <zip>61401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Illinois CancerCare - Cottage</name>
      <address>
        <city>Galesburg</city>
        <state>Illinois</state>
        <zip>61401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Illinois CancerCare - Galesburg</name>
      <address>
        <city>Galesburg</city>
        <state>Illinois</state>
        <zip>61401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Illinois CancerCare - Havana</name>
      <address>
        <city>Havana</city>
        <state>Illinois</state>
        <zip>62644</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mason District Hospital</name>
      <address>
        <city>Havana</city>
        <state>Illinois</state>
        <zip>62644</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Illinois CancerCare - Kewanee Clinic</name>
      <address>
        <city>Kewanee</city>
        <state>Illinois</state>
        <zip>61443</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Illinois CancerCare - Macomb</name>
      <address>
        <city>Macomb</city>
        <state>Illinois</state>
        <zip>61455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McDonough District Hospital</name>
      <address>
        <city>Macomb</city>
        <state>Illinois</state>
        <zip>61455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardinal Bernardin Cancer Center at Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Illinois CancerCare - Monmouth</name>
      <address>
        <city>Monmouth</city>
        <state>Illinois</state>
        <zip>61462</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OSF Holy Family Medical Center</name>
      <address>
        <city>Monmouth</city>
        <state>Illinois</state>
        <zip>61462</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Good Samaritan Regional Health Center</name>
      <address>
        <city>Mount Vernon</city>
        <state>Illinois</state>
        <zip>62864</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Edward Hospital Cancer Center</name>
      <address>
        <city>Naperville</city>
        <state>Illinois</state>
        <zip>60540</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BroMenn Regional Medical Center</name>
      <address>
        <city>Normal</city>
        <state>Illinois</state>
        <zip>61761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Cancer Center</name>
      <address>
        <city>Normal</city>
        <state>Illinois</state>
        <zip>61761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Illinois CancerCare - Community Cancer Center</name>
      <address>
        <city>Normal</city>
        <state>Illinois</state>
        <zip>61761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Hospital of Ottawa</name>
      <address>
        <city>Ottawa</city>
        <state>Illinois</state>
        <zip>61350</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology Associates of Central Illinois, PC - Ottawa</name>
      <address>
        <city>Ottawa</city>
        <state>Illinois</state>
        <zip>61350</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Illinois CancerCare - Pekin</name>
      <address>
        <city>Pekin</city>
        <state>Illinois</state>
        <zip>61603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Proctor Hospital</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Illinois Oncology Research Association</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology Associates of Central Illinois, PC - Peoria</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Medical Center of Illinois</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61636</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OSF St. Francis Medical Center</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Illinois CancerCare - Peru</name>
      <address>
        <city>Peru</city>
        <state>Illinois</state>
        <zip>61354</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Illinois Valley Community Hospital</name>
      <address>
        <city>Peru</city>
        <state>Illinois</state>
        <zip>61354</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Illinois CancerCare - Princeton</name>
      <address>
        <city>Princeton</city>
        <state>Illinois</state>
        <zip>61356</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Perry Memorial Hospital</name>
      <address>
        <city>Princeton</city>
        <state>Illinois</state>
        <zip>61356</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish-American Regional Cancer Center</name>
      <address>
        <city>Rockford</city>
        <state>Illinois</state>
        <zip>61104-2315</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Illinois CancerCare - Spring Valley</name>
      <address>
        <city>Spring Valley</city>
        <state>Illinois</state>
        <zip>61362</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Cancer Center at Memorial Medical Center</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62781-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Francis Hospital and Health Centers - Beech Grove Campus</name>
      <address>
        <city>Beech Grove</city>
        <state>Indiana</state>
        <zip>46107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elkhart Clinic, LLC</name>
      <address>
        <city>Elkhart</city>
        <state>Indiana</state>
        <zip>46514-2098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elkhart General Hospital</name>
      <address>
        <city>Elkhart</city>
        <state>Indiana</state>
        <zip>46515</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fort Wayne Medical Oncology and Hematology</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Cancer Care at Goshen General Hospital</name>
      <address>
        <city>Goshen</city>
        <state>Indiana</state>
        <zip>46526</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent Indianapolis Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Howard Community Hospital</name>
      <address>
        <city>Kokomo</city>
        <state>Indiana</state>
        <zip>46904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Cancer Therapy at LaPorte Hospital and Health Services</name>
      <address>
        <city>La Porte</city>
        <state>Indiana</state>
        <zip>46350</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Hospital</name>
      <address>
        <city>Munster</city>
        <state>Indiana</state>
        <zip>46321</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reid Hospital &amp; Health Care Services</name>
      <address>
        <city>Richmond</city>
        <state>Indiana</state>
        <zip>47374</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Northern Indiana CR Consortium</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Hospital of South Bend</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michiana Hematology-Oncology, PC - South Bend</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Joseph Regional Medical Center</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Bend Clinic</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McFarland Clinic, PC</name>
      <address>
        <city>Ames</city>
        <state>Iowa</state>
        <zip>50010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holden Comprehensive Cancer Center at University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242-1002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas, PA - Chanute</name>
      <address>
        <city>Chanute</city>
        <state>Kansas</state>
        <zip>66720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas, PA - Dodge City</name>
      <address>
        <city>Dodge City</city>
        <state>Kansas</state>
        <zip>67801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas, PA - El Dorado</name>
      <address>
        <city>El Dorado</city>
        <state>Kansas</state>
        <zip>67042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas - Fort Scott</name>
      <address>
        <city>Fort Scott</city>
        <state>Kansas</state>
        <zip>66701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas-Independence</name>
      <address>
        <city>Independence</city>
        <state>Kansas</state>
        <zip>67301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas, PA - Kingman</name>
      <address>
        <city>Kingman</city>
        <state>Kansas</state>
        <zip>67068</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lawrence Memorial Hospital</name>
      <address>
        <city>Lawrence</city>
        <state>Kansas</state>
        <zip>66044</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwest Medical Center</name>
      <address>
        <city>Liberal</city>
        <state>Kansas</state>
        <zip>67901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas, PA - Newton</name>
      <address>
        <city>Newton</city>
        <state>Kansas</state>
        <zip>67114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Menorah Medical Center</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Luke's Hospital - South</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas, PA - Parsons</name>
      <address>
        <city>Parsons</city>
        <state>Kansas</state>
        <zip>67357</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas, PA - Pratt</name>
      <address>
        <city>Pratt</city>
        <state>Kansas</state>
        <zip>67124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas, PA - Salina</name>
      <address>
        <city>Salina</city>
        <state>Kansas</state>
        <zip>67401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shawnee Mission Medical Center</name>
      <address>
        <city>Shawnee</city>
        <state>Kansas</state>
        <zip>66204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas, PA - Wellington</name>
      <address>
        <city>Wellington</city>
        <state>Kansas</state>
        <zip>67152</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Associates in Womens Health, PA - North Review</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas, PA - Medical Arts Tower</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas, PA - Wichita</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Wichita</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Via Christi Cancer Center at Via Christi Regional Medical Center</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wesley Medical Center</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas, PA - Winfield</name>
      <address>
        <city>Winfield</city>
        <state>Kansas</state>
        <zip>67156</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Resource Center at King's Daughters Medical Center</name>
      <address>
        <city>Ashland</city>
        <state>Kentucky</state>
        <zip>41101-0151</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lucille P. Markey Cancer Center at University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536-0093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louisville Oncology at Norton Cancer Institute - Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James Graham Brown Cancer Center at University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40292</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mary Bird Perkins Cancer Center - Baton Rouge</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ochsner Health Center - Bluebonnet</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MBCCOP - LSU Health Sciences Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center of Louisiana - New Orleans</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Ochsner</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ochsner Cancer Institute at Ochsner Clinic Foundation</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>York Hospital's Oncology Treatment Center</name>
      <address>
        <city>York</city>
        <state>Maine</state>
        <zip>03909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greenebaum Cancer Center at University of Maryland Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greater Baltimore Medical Center Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Agnes Hospital Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harry &amp; Jeanette Weinberg Cancer Institute at Franklin Square Hospital Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frederick Memorial Hospital Regional Cancer Therapy Center</name>
      <address>
        <city>Frederick</city>
        <state>Maryland</state>
        <zip>21701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Associates in Oncology and Hematology - Medical Center Drive</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20878</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peninsula Regional Medical Center</name>
      <address>
        <city>Salisbury</city>
        <state>Maryland</state>
        <zip>21801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MetroWest Medical Center - Framingham Union Hospital</name>
      <address>
        <city>Framingham</city>
        <state>Massachusetts</state>
        <zip>01702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hickman Cancer Center at Bixby Medical Center</name>
      <address>
        <city>Adrian</city>
        <state>Michigan</state>
        <zip>49221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Joseph Mercy Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48106-0995</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Michigan Cancer Research Consortium</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oakwood Cancer Center at Oakwood Hospital and Medical Center</name>
      <address>
        <city>Dearborn</city>
        <state>Michigan</state>
        <zip>48123-2500</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Josephine Ford Cancer Center at Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Genesys Hurley Cancer Institute</name>
      <address>
        <city>Flint</city>
        <state>Michigan</state>
        <zip>48503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hurley Medical Center</name>
      <address>
        <city>Flint</city>
        <state>Michigan</state>
        <zip>48503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Great Lakes Cancer Institute at McLaren Regional Medical Center</name>
      <address>
        <city>Flint</city>
        <state>Michigan</state>
        <zip>48532</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Van Elslander Cancer Center at St. John Hospital and Medical Center</name>
      <address>
        <city>Grosse Pointe Woods</city>
        <state>Michigan</state>
        <zip>48236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Foote Memorial Hospital</name>
      <address>
        <city>Jackson</city>
        <state>Michigan</state>
        <zip>49201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Borgess Medical Center</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Michigan Cancer Center</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007-3731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bronson Methodist Hospital</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haematology-Oncology Associates of Ohio and Michigan, PC</name>
      <address>
        <city>Lambertville</city>
        <state>Michigan</state>
        <zip>48144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Breslin Cancer Center at Ingham Regional Medical Center</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sparrow Regional Cancer Center</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48912-1811</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lapeer Regional Hospital</name>
      <address>
        <city>Lapeer</city>
        <state>Michigan</state>
        <zip>48446</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Mary Mercy Hospital</name>
      <address>
        <city>Livonia</city>
        <state>Michigan</state>
        <zip>48154</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Cancer Center of Monroe</name>
      <address>
        <city>Monroe</city>
        <state>Michigan</state>
        <zip>48162</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Memorial Hospital - Monroe</name>
      <address>
        <city>Monroe</city>
        <state>Michigan</state>
        <zip>48162</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph Mercy Oakland</name>
      <address>
        <city>Pontiac</city>
        <state>Michigan</state>
        <zip>48341-2985</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Regional Cancer Center at Mercy Hospital</name>
      <address>
        <city>Port Huron</city>
        <state>Michigan</state>
        <zip>48060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seton Cancer Institute at Saint Mary's - Saginaw</name>
      <address>
        <city>Saginaw</city>
        <state>Michigan</state>
        <zip>48601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lakeland Regional Cancer Care Center - St. Joseph</name>
      <address>
        <city>Saint Joseph</city>
        <state>Michigan</state>
        <zip>49085</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lakeside Cancer Specialists, PLLC</name>
      <address>
        <city>Saint Joseph</city>
        <state>Michigan</state>
        <zip>49085</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Cancer Institute at Providence Hospital - Southfield Campus</name>
      <address>
        <city>Southfield</city>
        <state>Michigan</state>
        <zip>48075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. John Macomb Hospital</name>
      <address>
        <city>Warren</city>
        <state>Michigan</state>
        <zip>48093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fairview Ridges Hospital</name>
      <address>
        <city>Burnsville</city>
        <state>Minnesota</state>
        <zip>55337</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy and Unity Cancer Center at Mercy Hospital</name>
      <address>
        <city>Coon Rapids</city>
        <state>Minnesota</state>
        <zip>55433</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duluth Clinic Cancer Center - Duluth</name>
      <address>
        <city>Duluth</city>
        <state>Minnesota</state>
        <zip>55805-1983</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Duluth</name>
      <address>
        <city>Duluth</city>
        <state>Minnesota</state>
        <zip>55805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miller - Dwan Medical Center</name>
      <address>
        <city>Duluth</city>
        <state>Minnesota</state>
        <zip>55805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fairview Southdale Hospital</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy and Unity Cancer Center at Unity Hospital</name>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <zip>55432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hutchinson Area Health Care</name>
      <address>
        <city>Hutchinson</city>
        <state>Minnesota</state>
        <zip>55350</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HealthEast Cancer Care at St. John's Hospital</name>
      <address>
        <city>Maplewood</city>
        <state>Minnesota</state>
        <zip>55109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesota Oncology Hematology, PA - Maplewood</name>
      <address>
        <city>Maplewood</city>
        <state>Minnesota</state>
        <zip>55109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Piper Cancer Institute at Abbott - Northwestern Hospital</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hennepin County Medical Center - Minneapolis</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55415</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hubert H. Humphrey Cancer Center at North Memorial Outpatient Center</name>
      <address>
        <city>Robbinsdale</city>
        <state>Minnesota</state>
        <zip>55422-2900</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Metro-Minnesota</name>
      <address>
        <city>Saint Louis Park</city>
        <state>Minnesota</state>
        <zip>55416</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Park Nicollet Cancer Center</name>
      <address>
        <city>Saint Louis Park</city>
        <state>Minnesota</state>
        <zip>55416</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regions Hospital Cancer Care Center</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>United Hospital</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Francis Cancer Center at St. Francis Medical Center</name>
      <address>
        <city>Shakopee</city>
        <state>Minnesota</state>
        <zip>55379</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ridgeview Medical Center</name>
      <address>
        <city>Waconia</city>
        <state>Minnesota</state>
        <zip>55387</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesota Oncology Hematology, PA - Woodbury</name>
      <address>
        <city>Woodbury</city>
        <state>Minnesota</state>
        <zip>55125</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hattiesburg Clinic, PA at Forrest General</name>
      <address>
        <city>Hattiesburg</city>
        <state>Mississippi</state>
        <zip>39401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Francis Medical Center</name>
      <address>
        <city>Cape Girardeau</city>
        <state>Missouri</state>
        <zip>63703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ellis Fischel Cancer Center at University of Missouri - Columbia</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. John's Regional Medical Center</name>
      <address>
        <city>Joplin</city>
        <state>Missouri</state>
        <zip>64804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Truman Medical Center - Hospital Hill</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Luke's Cancer Institute at Saint Luke's Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Kansas City Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64116</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parvin Radiation Oncology</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64116</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heartland Hematology Oncology Associates, Incorporated</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Kansas City</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Luke's East - Lee's Summit</name>
      <address>
        <city>Lee's Summit</city>
        <state>Missouri</state>
        <zip>64086</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liberty Hospital</name>
      <address>
        <city>Liberty</city>
        <state>Missouri</state>
        <zip>64068</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heartland Regional Medical Center</name>
      <address>
        <city>Saint Joseph</city>
        <state>Missouri</state>
        <zip>64506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Hematology Oncology Group, Incorporated</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Louis University Cancer Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - St. Louis-Cape Girardeau</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>David C. Pratt Cancer Center at St. John's Mercy</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Cancer Research for the Ozarks</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. John's Regional Health Center</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hulston Cancer Center at Cox Medical Center South</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Montana Cancer Consortium</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology-Oncology Centers of the Northern Rockies - Billings</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern Rockies Radiation Oncology Center</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent Healthcare Cancer Care Services</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Billings Clinic - Downtown</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59107-7000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bozeman Deaconess Cancer Center</name>
      <address>
        <city>Bozeman</city>
        <state>Montana</state>
        <zip>59715</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. James Healthcare Cancer Care</name>
      <address>
        <city>Butte</city>
        <state>Montana</state>
        <zip>59701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Big Sky Oncology</name>
      <address>
        <city>Great Falls</city>
        <state>Montana</state>
        <zip>59405-5309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Great Falls Clinic - Main Facility</name>
      <address>
        <city>Great Falls</city>
        <state>Montana</state>
        <zip>59405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sletten Cancer Institute at Benefis Healthcare</name>
      <address>
        <city>Great Falls</city>
        <state>Montana</state>
        <zip>59405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Great Falls</city>
        <state>Montana</state>
        <zip>59405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Peter's Hospital</name>
      <address>
        <city>Helena</city>
        <state>Montana</state>
        <zip>59601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glacier Oncology, PLLC</name>
      <address>
        <city>Kalispell</city>
        <state>Montana</state>
        <zip>59901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kalispell Medical Oncology at KRMC</name>
      <address>
        <city>Kalispell</city>
        <state>Montana</state>
        <zip>59901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kalispell Regional Medical Center</name>
      <address>
        <city>Kalispell</city>
        <state>Montana</state>
        <zip>59901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Medical Center</name>
      <address>
        <city>Missoula</city>
        <state>Montana</state>
        <zip>59801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guardian Oncology and Center for Wellness</name>
      <address>
        <city>Missoula</city>
        <state>Montana</state>
        <zip>59804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montana Cancer Specialists at Montana Cancer Center</name>
      <address>
        <city>Missoula</city>
        <state>Montana</state>
        <zip>59807-7877</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montana Cancer Center at St. Patrick Hospital and Health Sciences Center</name>
      <address>
        <city>Missoula</city>
        <state>Montana</state>
        <zip>59807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Good Samaritan Cancer Center at Good Samaritan Hospital</name>
      <address>
        <city>Kearney</city>
        <state>Nebraska</state>
        <zip>68848-1990</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Resource Center - Lincoln</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Missouri Valley Cancer Consortium</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Immanuel Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alegant Health Cancer Center at Bergan Mercy Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Creighton University Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131-2197</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Institute of New Jersey at Hamilton</name>
      <address>
        <city>Hamilton</city>
        <state>New Jersey</state>
        <zip>08690</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newark Beth Israel Medical Center</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Institute of New Jersey at Cooper - Voorhees</name>
      <address>
        <city>Voorhees</city>
        <state>New Jersey</state>
        <zip>08043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charles R. Wood Cancer Center at Glens Falls Hospital</name>
      <address>
        <city>Glens Falls</city>
        <state>New York</state>
        <zip>12801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tucker Center for Cancer Care at Orange Regional Medical Center</name>
      <address>
        <city>Middletown</city>
        <state>New York</state>
        <zip>10940-4199</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Francis Hospital Cancer Center</name>
      <address>
        <city>Poughkeepsie</city>
        <state>New York</state>
        <zip>12601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Our Lady of Mercy Medical Center Comprehensive Cancer Center</name>
      <address>
        <city>The Bronx</city>
        <state>New York</state>
        <zip>10466</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Randolph Hospital</name>
      <address>
        <city>Asheboro</city>
        <state>North Carolina</state>
        <zip>27203-5400</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hope A Women's Cancer Center</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28816</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alamance Cancer Center at Alamance Regional Medical Center</name>
      <address>
        <city>Burlington</city>
        <state>North Carolina</state>
        <zip>27216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blumenthal Cancer Center at Carolinas Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28232-2861</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Presbyterian Cancer Center at Presbyterian Hospital</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28233-3549</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Batte Cancer Center at Northeast Medical Center</name>
      <address>
        <city>Concord</city>
        <state>North Carolina</state>
        <zip>28025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne Memorial Hospital, Incorporated</name>
      <address>
        <city>Goldsboro</city>
        <state>North Carolina</state>
        <zip>27534</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moses Cone Regional Cancer Center at Wesley Long Community Hospital</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27403-1198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Annie Penn Cancer Center</name>
      <address>
        <city>Reidsville</city>
        <state>North Carolina</state>
        <zip>27320</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rutherford Hospital</name>
      <address>
        <city>Rutherfordton</city>
        <state>North Carolina</state>
        <zip>28139</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iredell Memorial Hospital</name>
      <address>
        <city>Statesville</city>
        <state>North Carolina</state>
        <zip>28677</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marion L. Shepard Cancer Center at Beaufort County Hospital</name>
      <address>
        <city>Washington</city>
        <state>North Carolina</state>
        <zip>27889</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forsyth Regional Cancer Center at Forsyth Medical Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Comprehensive Cancer Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157-1096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altru Cancer Center at Altru Hospital</name>
      <address>
        <city>Grand Forks</city>
        <state>North Dakota</state>
        <zip>58201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McDowell Cancer Center at Akron General Medical Center</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44307</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Summa Center for Cancer Care at Akron City Hospital</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44309-2090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barberton Citizens Hospital</name>
      <address>
        <city>Barberton</city>
        <state>Ohio</state>
        <zip>44203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wood County Oncology Center</name>
      <address>
        <city>Bowling Green</city>
        <state>Ohio</state>
        <zip>43402</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aultman Cancer Center at Aultman Hospital</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44710-1799</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Coast Cancer Care - Clyde</name>
      <address>
        <city>Clyde</city>
        <state>Ohio</state>
        <zip>43410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210-1240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grandview Hospital</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Good Samaritan Hospital</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>David L. Rike Cancer Center at Miami Valley Hospital</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samaritan North Cancer Care Center</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45415</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Dayton</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45420</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Cancer Center</name>
      <address>
        <city>Elyria</city>
        <state>Ohio</state>
        <zip>44035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology Oncology Center</name>
      <address>
        <city>Elyria</city>
        <state>Ohio</state>
        <zip>44035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blanchard Valley Medical Associates</name>
      <address>
        <city>Findlay</city>
        <state>Ohio</state>
        <zip>45840</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Middletown Regional Hospital</name>
      <address>
        <city>Franklin</city>
        <state>Ohio</state>
        <zip>45005-1066</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne Hospital</name>
      <address>
        <city>Greenville</city>
        <state>Ohio</state>
        <zip>45331</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charles F. Kettering Memorial Hospital</name>
      <address>
        <city>Kettering</city>
        <state>Ohio</state>
        <zip>45429</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lima Memorial Hospital</name>
      <address>
        <city>Lima</city>
        <state>Ohio</state>
        <zip>45804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Ohio Oncology Center</name>
      <address>
        <city>Maumee</city>
        <state>Ohio</state>
        <zip>43537-1839</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Hospital</name>
      <address>
        <city>Maumee</city>
        <state>Ohio</state>
        <zip>43537</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fisher-Titus Medical Center</name>
      <address>
        <city>Norwalk</city>
        <state>Ohio</state>
        <zip>44857</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Charles Mercy Hospital</name>
      <address>
        <city>Oregon</city>
        <state>Ohio</state>
        <zip>43616</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toledo Clinic - Oregon</name>
      <address>
        <city>Oregon</city>
        <state>Ohio</state>
        <zip>43616</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Center, Incorporated</name>
      <address>
        <city>Salem</city>
        <state>Ohio</state>
        <zip>44460</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Coast Cancer Care, Incorporated</name>
      <address>
        <city>Sandusky</city>
        <state>Ohio</state>
        <zip>44870</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Flower Hospital Cancer Center</name>
      <address>
        <city>Sylvania</city>
        <state>Ohio</state>
        <zip>43560</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Hospital of Tiffin</name>
      <address>
        <city>Tiffin</city>
        <state>Ohio</state>
        <zip>44883</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toledo Hospital</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent Mercy Medical Center</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Ohio Cancer Center</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Toledo Community Hospital</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Anne Mercy Hospital</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43623</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toledo Clinic, Incorporated - Main Clinic</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43623</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UVMC Cancer Care Center at Upper Valley Medical Center</name>
      <address>
        <city>Troy</city>
        <state>Ohio</state>
        <zip>45373-1300</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fulton County Health Center</name>
      <address>
        <city>Wauseon</city>
        <state>Ohio</state>
        <zip>43567</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinton Memorial Hospital</name>
      <address>
        <city>Wilmington</city>
        <state>Ohio</state>
        <zip>45177</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Treatment Center</name>
      <address>
        <city>Wooster</city>
        <state>Ohio</state>
        <zip>44691</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruth G. McMillan Cancer Center at Greene Memorial Hospital</name>
      <address>
        <city>Xenia</city>
        <state>Ohio</state>
        <zip>45385</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleo Craig Cancer Research Clinic</name>
      <address>
        <city>Lawton</city>
        <state>Oklahoma</state>
        <zip>73505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Health Care - Portland</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Morgan Cancer Center at Lehigh Valley Hospital - Cedar Crest</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Cancer Network at St. Luke's Hospital</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bryn Mawr Hospital</name>
      <address>
        <city>Bryn Mawr</city>
        <state>Pennsylvania</state>
        <zip>19010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geisinger Cancer Institute at Geisinger Health</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cherry Tree Cancer Center</name>
      <address>
        <city>Hanover</city>
        <state>Pennsylvania</state>
        <zip>17331</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State Cancer Institute at Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033-0850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Paoli Memorial Hospital</name>
      <address>
        <city>Paoli</city>
        <state>Pennsylvania</state>
        <zip>19301-1792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allegheny Cancer Center at Allegheny General Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Pennsylvania Cancer Institute at Western Pennsylvania Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224-1791</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC Cancer Centers</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGlinn Family Regional Cancer Center at Reading Hospital and Medical Center</name>
      <address>
        <city>Reading</city>
        <state>Pennsylvania</state>
        <zip>19612-6052</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geisinger Medical Group - Scenery Park</name>
      <address>
        <city>State College</city>
        <state>Pennsylvania</state>
        <zip>16801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Nittany Medical Center</name>
      <address>
        <city>State College</city>
        <state>Pennsylvania</state>
        <zip>16803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center</name>
      <address>
        <city>Wilkes-Barre</city>
        <state>Pennsylvania</state>
        <zip>18711</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Main Line Health</name>
      <address>
        <city>Wynnewood</city>
        <state>Pennsylvania</state>
        <zip>19096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lankenau Cancer Center at Lankenau Hospital</name>
      <address>
        <city>Wynnewood</city>
        <state>Pennsylvania</state>
        <zip>19096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>York Cancer Center at Apple Hill Medical Center</name>
      <address>
        <city>York</city>
        <state>Pennsylvania</state>
        <zip>17405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AnMed Cancer Center</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roper St. Francis Cancer Center at Roper Hospital</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hollings Cancer Center at Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Greenville</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Upstate Carolina</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gibbs Regional Cancer Center at Spartanburg Regional Medical Center</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical X-Ray Center, PC</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanford Cancer Center at Sanford USD Medical Center</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57117-5039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thompson Cancer Survival Center</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37916</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Tennessee Cancer Institute - Memphis</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nashville Oncology Associates, PC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MBCCOP - Meharry Medical College - Nashville</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37208-3599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Doctor's Hospital of Laredo</name>
      <address>
        <city>Laredo</city>
        <state>Texas</state>
        <zip>78041</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229-3900</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>American Fork Hospital</name>
      <address>
        <city>American Fork</city>
        <state>Utah</state>
        <zip>84003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandra L. Maxwell Cancer Center</name>
      <address>
        <city>Cedar City</city>
        <state>Utah</state>
        <zip>84720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jon and Karen Huntsman Cancer Center at Intermountain Medical Center</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Val and Ann Browning Cancer Center at McKay-Dee Hospital Center</name>
      <address>
        <city>Ogden</city>
        <state>Utah</state>
        <zip>84403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Utah Valley Regional Medical Center - Provo</name>
      <address>
        <city>Provo</city>
        <state>Utah</state>
        <zip>84604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dixie Regional Medical Center - East Campus</name>
      <address>
        <city>Saint George</city>
        <state>Utah</state>
        <zip>84770</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LDS Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Utah Cancer Specialists at UCS Cancer Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute at University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mountainview Medical</name>
      <address>
        <city>Berlin Corners</city>
        <state>Vermont</state>
        <zip>05602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fletcher Allen Health Care - University Health Center Campus</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fredericksburg Oncology, Incorporated</name>
      <address>
        <city>Fredericksburg</city>
        <state>Virginia</state>
        <zip>22401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University Massey Cancer Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298-0037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auburn Regional Center for Cancer Care</name>
      <address>
        <city>Auburn</city>
        <state>Washington</state>
        <zip>98002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Centralia Hospital</name>
      <address>
        <city>Centralia</city>
        <state>Washington</state>
        <zip>98531-9027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Francis Hospital</name>
      <address>
        <city>Federal Way</city>
        <state>Washington</state>
        <zip>98003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence St. Peter Hospital Regional Cancer Center</name>
      <address>
        <city>Olympia</city>
        <state>Washington</state>
        <zip>98506-5166</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Good Samaritan Cancer Center</name>
      <address>
        <city>Puyallup</city>
        <state>Washington</state>
        <zip>98372</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Franciscan Cancer Center at St. Joseph Medical Center</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405-3004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allenmore Hospital</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Northwest</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MultiCare Regional Cancer Center at Tacoma General Hospital</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Clare Hospital</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98499</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Virginia University Health Sciences Center - Charleston</name>
      <address>
        <city>Charleston</city>
        <state>West Virginia</state>
        <zip>25304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mary Babb Randolph Cancer Center at West Virginia University Hospitals</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Comprehensive Cancer Center at Camden-Clark Memorial Hospital</name>
      <address>
        <city>Parkersburg</city>
        <state>West Virginia</state>
        <zip>26102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marshfield Clinic - Chippewa Center</name>
      <address>
        <city>Chippewa Falls</city>
        <state>Wisconsin</state>
        <zip>54729</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marshfield Clinic Cancer Care at Regional Cancer Center</name>
      <address>
        <city>Eau Claire</city>
        <state>Wisconsin</state>
        <zip>54701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vince Lombardi Cancer Clinic - Green Bay at Aurora BayCare Medical Center</name>
      <address>
        <city>Green Bay</city>
        <state>Wisconsin</state>
        <zip>54311</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gundersen Lutheran Center for Cancer and Blood</name>
      <address>
        <city>La Crosse</city>
        <state>Wisconsin</state>
        <zip>54601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marshfield Clinic - Marshfield Center</name>
      <address>
        <city>Marshfield</city>
        <state>Wisconsin</state>
        <zip>54449</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Joseph's Hospital</name>
      <address>
        <city>Marshfield</city>
        <state>Wisconsin</state>
        <zip>54449</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aurora Sinai Medical Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53201-0342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin Cancer Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marshfield Clinic - Lakeland Center</name>
      <address>
        <city>Minocqua</city>
        <state>Wisconsin</state>
        <zip>54548</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vince Lombardi Cancer Clinic - Oshkosh</name>
      <address>
        <city>Oshkosh</city>
        <state>Wisconsin</state>
        <zip>54904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ministry Medical Group at Saint Mary's Hospital</name>
      <address>
        <city>Rhinelander</city>
        <state>Wisconsin</state>
        <zip>54501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marshfield Clinic - Indianhead Center</name>
      <address>
        <city>Rice Lake</city>
        <state>Wisconsin</state>
        <zip>54868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marshfield Clinic at Saint Michael's Hospital</name>
      <address>
        <city>Stevens Point</city>
        <state>Wisconsin</state>
        <zip>54481</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marshfield Clinic - Wausau Center</name>
      <address>
        <city>Wausau</city>
        <state>Wisconsin</state>
        <zip>54401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aurora Women's Pavilion of West Allis Memorial Hospital</name>
      <address>
        <city>West Allis</city>
        <state>Wisconsin</state>
        <zip>53227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marshfield Clinic - Weston Center</name>
      <address>
        <city>Weston</city>
        <state>Wisconsin</state>
        <zip>54476</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marshfield Clinic - Wisconsin Rapids Center</name>
      <address>
        <city>Wisconsin Rapids</city>
        <state>Wisconsin</state>
        <zip>54494</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Welch Cancer Center at Sheridan Memorial Hospital</name>
      <address>
        <city>Sheridan</city>
        <state>Wyoming</state>
        <zip>82801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Edmond Odette Cancer Centre at Sunnybrook</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Notre-Dame du CHUM</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUM - Hotel Dieu Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1T8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUM - Hopital Saint-Luc</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 3J4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Hospital - Montreal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 1A1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3G 1A4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital - Montreal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Mary's Hospital Center</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital du Saint-Sacrement - Quebec</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1S 4L8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Juan City Hospital</name>
      <address>
        <city>San Juan</city>
        <zip>00928</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Bear HD, Tang G, Rastogi P, Geyer CE Jr, Robidoux A, Atkins JN, Baez-Diaz L, Brufsky AM, Mehta RS, Fehrenbacher L, Young JA, Senecal FM, Gaur R, Margolese RG, Adams PT, Gross HM, Costantino JP, Swain SM, Mamounas EP, Wolmark N. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med. 2012 Jan 26;366(4):310-20. doi: 10.1056/NEJMoa1111097.</citation>
    <PMID>22276821</PMID>
  </results_reference>
  <results_reference>
    <citation>Bear HD, Tang G, Rastogi P, et al.: The effect on pCR of bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy: NSABP protocol B-40. [Abstract] J Clin Oncol 29 (Suppl 15): A-LBA1005, 2011.</citation>
  </results_reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 6, 2006</study_first_submitted>
  <study_first_submitted_qc>December 6, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2006</study_first_posted>
  <results_first_submitted>March 23, 2017</results_first_submitted>
  <results_first_submitted_qc>September 12, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">September 18, 2017</results_first_posted>
  <last_update_submitted>September 12, 2017</last_update_submitted>
  <last_update_submitted_qc>September 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm 1A: Docetaxel Then AC</title>
          <description>Patients receive docetaxel IV on day 1 every 3 weeks for up to 4 cycles. Patients then receive AC IV every 3 weeks for up to 4 cycles. Patients then undergo surgery (lumpectomy or mastectomy).
cyclophosphamide: 600 mg/m2 IV
docetaxel: 100 mg/m2 IV
doxorubicin hydrochloride (Adriamycin): 60 mg/m2 IV</description>
        </group>
        <group group_id="P2">
          <title>Arm 1B Docetaxel + Bev Then AC + Bev</title>
          <description>Patients receive bevacizumab (bev) IV on day 1 and docetaxel every 3 weeks for up to 4 cycles. Patients then receive AC every 3 weeks for up to 4 cycles and 2 additional cycles of bevacizumab concurrent with the first 2 cycles of AC. Patients then undergo surgery as in Arm 1A. At least 4-6 weeks after surgery, patients receive adjuvant bevacizumab IV every 3 weeks for up to 10 cycles in the absence of disease progression or unacceptable toxicity.
bevacizumab: 15 mg/kg IV
cyclophosphamide: 600 mg/m2 IV
docetaxel: 100 mg/m2 IV
doxorubicin hydrochloride (Adriamycin): 60 mg/m2 IV</description>
        </group>
        <group group_id="P3">
          <title>Arm 2A: Docetaxel + Capecitabine Then AC</title>
          <description>Patients receive docetaxel as in Arm 1A and oral capecitabine (cape) twice daily on days 1-14 every 3 weeks for up to 4 cycles. Patients then receive AC as in Arm 1A. Patients then undergo surgery as in Arm 1A.
capecitabine: 825 mg/m2 orally
cyclophosphamide: 600 mg/m2 IV
docetaxel: 100 mg/m2 IV
doxorubicin hydrochloride (Adriamycin): 60 mg/m2 IV</description>
        </group>
        <group group_id="P4">
          <title>Arm 2B: Docetaxel + Cape + Bev Then AC + Bev</title>
          <description>Patients receive bevacizumab as in Arm 1B and docetaxel and capecitabine as in Arm III. Treatment repeats every 3 weeks for up to 4 cycles. Patients then receive AC every 3 weeks for up to 4 cycles and 2 additional cycles of bevacizumab concurrent with the first 2 cycles of AC. Patients then undergo surgery as in Arm 1B. At least 4-6 weeks after surgery, patients receive adjuvant bevacizumab as in Arm 1B.
bevacizumab: 15 mg/kg IV
capecitabine: 825 mg/m2 orally
cyclophosphamide: 600 mg/m2 IV
docetaxel: 100 mg/m2 IV
doxorubicin hydrochloride (Adriamycin): 60 mg/m2 IV</description>
        </group>
        <group group_id="P5">
          <title>Arm 3A: Docetaxel + Gem Then AC</title>
          <description>Patients receive docetaxel as in Arm 1A and gemcitabine hydrochloride IV on days 1 and 8 of each cycle every 3 weeks for up to 4 cycles. Patients then receive AC as in Arm 1A. Patients then undergo surgery as in Arm 1A.
cyclophosphamide: 600 mg/m2 IV
docetaxel: 100 mg/m2 IV
doxorubicin hydrochloride (Adriamycin): 60 mg/m2 IV
gemcitabine hydrochloride: 1000 mg/m2 IV</description>
        </group>
        <group group_id="P6">
          <title>Arm 3B: Docetaxel + Gem + Bev Then AC + Bev</title>
          <description>Patients receive docetaxel as in Arm 1A, gemcitabine hydrochloride as in Arm 3A, and bevacizumab as in Arm 1B. Patients then receive AC every 3 weeks for up to 4 cycles and 2 additional cycles of bevacizumab concurrent with the first 2 cycles of AC. Patients then undergo surgery as in Arm 1A. At least 4-6 weeks after surgery, patients receive adjuvant bevacizumab as in Arm 1B.
bevacizumab: 15 mg/kg IV
cyclophosphamide: 600 mg/m2 IV
docetaxel: 100 mg/m2 IV
doxorubicin hydrochloride (Adriamycin): 60 mg/m2 IV
gemcitabine hydrochloride: 1000 mg/m2 IV</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="201"/>
                <participants group_id="P2" count="199"/>
                <participants group_id="P3" count="204"/>
                <participants group_id="P4" count="201"/>
                <participants group_id="P5" count="197"/>
                <participants group_id="P6" count="204"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="199"/>
                <participants group_id="P2" count="196"/>
                <participants group_id="P3" count="204"/>
                <participants group_id="P4" count="194"/>
                <participants group_id="P5" count="192"/>
                <participants group_id="P6" count="201"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>No follow up data</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Docetaxel Then AC</title>
          <description>Docetaxel then AC</description>
        </group>
        <group group_id="B2">
          <title>Docetaxel + Bev Then AC + Bev</title>
          <description>Docetaxel + Bev then AC + Bev</description>
        </group>
        <group group_id="B3">
          <title>Docetaxel + Capecitabine Then AC</title>
          <description>Docetaxel + Capecitabine then AC</description>
        </group>
        <group group_id="B4">
          <title>Docetaxel + Cape + Bev Then AC + Bev</title>
          <description>Docetaxel + Cape + Bev then AC + Bev</description>
        </group>
        <group group_id="B5">
          <title>Docetaxel + Gem Then AC</title>
          <description>Docetaxel + Gem then AC</description>
        </group>
        <group group_id="B6">
          <title>Docetaxel + Gem + Bev Then AC + Bev</title>
          <description>Docetaxel + Gem + Bev then AC + Bev</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="201"/>
            <count group_id="B2" value="199"/>
            <count group_id="B3" value="204"/>
            <count group_id="B4" value="201"/>
            <count group_id="B5" value="197"/>
            <count group_id="B6" value="204"/>
            <count group_id="B7" value="1206"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48" spread="9.1"/>
                    <measurement group_id="B2" value="49" spread="9.6"/>
                    <measurement group_id="B3" value="49" spread="9.8"/>
                    <measurement group_id="B4" value="49" spread="10.4"/>
                    <measurement group_id="B5" value="48" spread="9.9"/>
                    <measurement group_id="B6" value="48" spread="9.8"/>
                    <measurement group_id="B7" value="48" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="201"/>
                    <measurement group_id="B2" value="199"/>
                    <measurement group_id="B3" value="204"/>
                    <measurement group_id="B4" value="201"/>
                    <measurement group_id="B5" value="197"/>
                    <measurement group_id="B6" value="204"/>
                    <measurement group_id="B7" value="1206"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pathologic Complete Response (pCR) of the Primary Tumor in the Breast</title>
        <description>Percentage of patients absent of histologic evidence of invasive tumor cells in the surgical breast specimen.</description>
        <time_frame>Time of surgery, on average 6 or 13 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1A: Docetaxel Then AC</title>
            <description>Patients receive docetaxel IV on day 1 every 3 weeks for up to 4 cycles. Patients then receive AC IV every 3 weeks for up to 4 cycles. Patients then undergo surgery (lumpectomy or mastectomy).
cyclophosphamide: 600 mg/m2 IV
docetaxel: 100 mg/m2 IV
doxorubicin hydrochloride (Adriamycin): 60 mg/m2 IV</description>
          </group>
          <group group_id="O2">
            <title>Arm 1B Docetaxel + Bev Then AC + Bev</title>
            <description>Patients receive bevacizumab (bev) IV on day 1 and docetaxel every 3 weeks for up to 4 cycles. Patients then receive AC every 3 weeks for up to 4 cycles and 2 additional cycles of bevacizumab concurrent with the first 2 cycles of AC. Patients then undergo surgery as in Arm 1A. At least 4-6 weeks after surgery, patients receive adjuvant bevacizumab IV every 3 weeks for up to 10 cycles in the absence of disease progression or unacceptable toxicity.
bevacizumab: 15 mg/kg IV
cyclophosphamide: 600 mg/m2 IV
docetaxel: 100 mg/m2 IV
doxorubicin hydrochloride (Adriamycin): 60 mg/m2 IV</description>
          </group>
          <group group_id="O3">
            <title>Arm 2A: Docetaxel + Capecitabine Then AC</title>
            <description>Patients receive docetaxel as in Arm 1A and oral capecitabine (cape) twice daily on days 1-14 every 3 weeks for up to 4 cycles. Patients then receive AC as in Arm 1A. Patients then undergo surgery as in Arm 1A.
capecitabine: 825 mg/m2 orally
cyclophosphamide: 600 mg/m2 IV
docetaxel: 100 mg/m2 IV
doxorubicin hydrochloride (Adriamycin): 60 mg/m2 IV</description>
          </group>
          <group group_id="O4">
            <title>Arm 2B: Docetaxel + Cape + Bev Then AC + Bev</title>
            <description>Patients receive bevacizumab as in Arm 1B and docetaxel and capecitabine as in Arm III. Treatment repeats every 3 weeks for up to 4 cycles. Patients then receive AC every 3 weeks for up to 4 cycles and 2 additional cycles of bevacizumab concurrent with the first 2 cycles of AC. Patients then undergo surgery as in Arm 1B. At least 4-6 weeks after surgery, patients receive adjuvant bevacizumab as in Arm 1B.
bevacizumab: 15 mg/kg IV
capecitabine: 825 mg/m2 orally
cyclophosphamide: 600 mg/m2 IV
docetaxel: 100 mg/m2 IV
doxorubicin hydrochloride (Adriamycin): 60 mg/m2 IV</description>
          </group>
          <group group_id="O5">
            <title>Arm 3A: Docetaxel + Gem Then AC</title>
            <description>Patients receive docetaxel as in Arm 1A and gemcitabine hydrochloride IV on days 1 and 8 of each cycle every 3 weeks for up to 4 cycles. Patients then receive AC as in Arm 1A. Patients then undergo surgery as in Arm 1A.
cyclophosphamide: 600 mg/m2 IV
docetaxel: 100 mg/m2 IV
doxorubicin hydrochloride (Adriamycin): 60 mg/m2 IV
gemcitabine hydrochloride: 1000 mg/m2 IV</description>
          </group>
          <group group_id="O6">
            <title>Arm 3B: Docetaxel + Gem + Bev Then AC + Bev</title>
            <description>Patients receive docetaxel as in Arm 1A, gemcitabine hydrochloride as in Arm 3A, and bevacizumab as in Arm 1B. Patients then receive AC every 3 weeks for up to 4 cycles and 2 additional cycles of bevacizumab concurrent with the first 2 cycles of AC. Patients then undergo surgery as in Arm 1A. At least 4-6 weeks after surgery, patients receive adjuvant bevacizumab as in Arm 1B.
bevacizumab: 15 mg/kg IV
cyclophosphamide: 600 mg/m2 IV
docetaxel: 100 mg/m2 IV
doxorubicin hydrochloride (Adriamycin): 60 mg/m2 IV
gemcitabine hydrochloride: 1000 mg/m2 IV</description>
          </group>
        </group_list>
        <measure>
          <title>Pathologic Complete Response (pCR) of the Primary Tumor in the Breast</title>
          <description>Percentage of patients absent of histologic evidence of invasive tumor cells in the surgical breast specimen.</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="199"/>
                <count group_id="O2" value="196"/>
                <count group_id="O3" value="204"/>
                <count group_id="O4" value="194"/>
                <count group_id="O5" value="192"/>
                <count group_id="O6" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.7" lower_limit="27.1" upper_limit="40.2"/>
                    <measurement group_id="O2" value="31.6" lower_limit="25.1" upper_limit="38.1"/>
                    <measurement group_id="O3" value="23.5" lower_limit="17.7" upper_limit="29.4"/>
                    <measurement group_id="O4" value="36.1" lower_limit="29.3" upper_limit="42.8"/>
                    <measurement group_id="O5" value="27.6" lower_limit="21.3" upper_limit="33.9"/>
                    <measurement group_id="O6" value="35.8" lower_limit="29.2" upper_limit="42.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>pCR in the Breast and Nodes</title>
        <description>Percentage of patients absent of histologic evidence of invasive tumor cells in the surgical breast specimen and axillary lymph nodes.</description>
        <time_frame>Time of surgery, on average 6 or 13 months</time_frame>
        <population>Arm 1A there is no follow up data for 3 patients; Arm 1B no follow up date for 6 patients; Arm 2A no follow up data for 1 patient; Arm 2B no follow up data for 11 patients; Arm 3A no follow up data for 9 patients; and Arm 3B no follow up data for 6 patients</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1A: Docetaxel Then AC</title>
            <description>Patients receive docetaxel IV on day 1 every 3 weeks for up to 4 cycles. Patients then receive AC IV every 3 weeks for up to 4 cycles. Patients then undergo surgery (lumpectomy or mastectomy).
cyclophosphamide: 600 mg/m2 IV
docetaxel: 100 mg/m2 IV
doxorubicin hydrochloride (Adriamycin): 60 mg/m2 IV</description>
          </group>
          <group group_id="O2">
            <title>Arm 1B Docetaxel + Bev Then AC + Bev</title>
            <description>Patients receive bevacizumab (bev) IV on day 1 and docetaxel every 3 weeks for up to 4 cycles. Patients then receive AC every 3 weeks for up to 4 cycles and 2 additional cycles of bevacizumab concurrent with the first 2 cycles of AC. Patients then undergo surgery as in Arm 1A. At least 4-6 weeks after surgery, patients receive adjuvant bevacizumab IV every 3 weeks for up to 10 cycles in the absence of disease progression or unacceptable toxicity.
bevacizumab: 15 mg/kg IV
cyclophosphamide: 600 mg/m2 IV
docetaxel: 100 mg/m2 IV
doxorubicin hydrochloride (Adriamycin): 60 mg/m2 IV</description>
          </group>
          <group group_id="O3">
            <title>Arm 2A: Docetaxel + Capecitabine Then AC</title>
            <description>Patients receive docetaxel as in Arm 1A and oral capecitabine (cape) twice daily on days 1-14 every 3 weeks for up to 4 cycles. Patients then receive AC as in Arm 1A. Patients then undergo surgery as in Arm 1A.
capecitabine: 825 mg/m2 orally
cyclophosphamide: 600 mg/m2 IV
docetaxel: 100 mg/m2 IV
doxorubicin hydrochloride (Adriamycin): 60 mg/m2 IV</description>
          </group>
          <group group_id="O4">
            <title>Arm 2B: Docetaxel + Cape + Bev Then AC + Bev</title>
            <description>Patients receive bevacizumab as in Arm 1B and docetaxel and capecitabine as in Arm III. Treatment repeats every 3 weeks for up to 4 cycles. Patients then receive AC every 3 weeks for up to 4 cycles and 2 additional cycles of bevacizumab concurrent with the first 2 cycles of AC. Patients then undergo surgery as in Arm 1B. At least 4-6 weeks after surgery, patients receive adjuvant bevacizumab as in Arm 1B.
bevacizumab: 15 mg/kg IV
capecitabine: 825 mg/m2 orally
cyclophosphamide: 600 mg/m2 IV
docetaxel: 100 mg/m2 IV
doxorubicin hydrochloride (Adriamycin): 60 mg/m2 IV</description>
          </group>
          <group group_id="O5">
            <title>Arm 3A: Docetaxel + Gem Then AC</title>
            <description>Patients receive docetaxel as in Arm 1A and gemcitabine hydrochloride IV on days 1 and 8 of each cycle every 3 weeks for up to 4 cycles. Patients then receive AC as in Arm 1A. Patients then undergo surgery as in Arm 1A.
cyclophosphamide: 600 mg/m2 IV
docetaxel: 100 mg/m2 IV
doxorubicin hydrochloride (Adriamycin): 60 mg/m2 IV
gemcitabine hydrochloride: 1000 mg/m2 IV</description>
          </group>
          <group group_id="O6">
            <title>Arm 3B: Docetaxel + Gem + Bev Then AC + Bev</title>
            <description>Patients receive docetaxel as in Arm 1A, gemcitabine hydrochloride as in Arm 3A, and bevacizumab as in Arm 1B. Patients then receive AC every 3 weeks for up to 4 cycles and 2 additional cycles of bevacizumab concurrent with the first 2 cycles of AC. Patients then undergo surgery as in Arm 1A. At least 4-6 weeks after surgery, patients receive adjuvant bevacizumab as in Arm 1B.
bevacizumab: 15 mg/kg IV
cyclophosphamide: 600 mg/m2 IV
docetaxel: 100 mg/m2 IV
doxorubicin hydrochloride (Adriamycin): 60 mg/m2 IV
gemcitabine hydrochloride: 1000 mg/m2 IV</description>
          </group>
        </group_list>
        <measure>
          <title>pCR in the Breast and Nodes</title>
          <description>Percentage of patients absent of histologic evidence of invasive tumor cells in the surgical breast specimen and axillary lymph nodes.</description>
          <population>Arm 1A there is no follow up data for 3 patients; Arm 1B no follow up date for 6 patients; Arm 2A no follow up data for 1 patient; Arm 2B no follow up data for 11 patients; Arm 3A no follow up data for 9 patients; and Arm 3B no follow up data for 6 patients</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="198"/>
                <count group_id="O2" value="193"/>
                <count group_id="O3" value="203"/>
                <count group_id="O4" value="190"/>
                <count group_id="O5" value="188"/>
                <count group_id="O6" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.3" lower_limit="21.3" upper_limit="33.6"/>
                    <measurement group_id="O2" value="24.4" lower_limit="18.6" upper_limit="30.6"/>
                    <measurement group_id="O3" value="18.7" lower_limit="13.7" upper_limit="24.4"/>
                    <measurement group_id="O4" value="27.4" lower_limit="21.2" upper_limit="33.8"/>
                    <measurement group_id="O5" value="22.9" lower_limit="17.2" upper_limit="29.1"/>
                    <measurement group_id="O6" value="30.3" lower_limit="24.1" upper_limit="36.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Overall Response (cOR) Following Docetaxel Alone, Docetaxel/Capecitabine, and Docetaxel/Gemcitabine Hydrochloride, With or Without Bevacizumab, as Assessed by Physical Exam at the Completion of the Docetaxel-based Portion of Chemotherapy</title>
        <description>Percentages of patients assessed as Clinical Complete Response or Clinical Partial Response according to RECIST.</description>
        <time_frame>Assessed at cycle 5 of chemotherapy, on average at 15 weeks</time_frame>
        <population>For Arm 1A there is no follow up data for 1 patient; Arm 1B no follow up data for 5 patients; Arm 2A no follow up data for 6 patients; Arm 2B no follow up data for 7 patients; Arm 3A no follow up data for 7 patients; Arm 3B no follow up data for 4 patients</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1A: Docetaxel Then AC</title>
            <description>Patients receive docetaxel IV on day 1 every 3 weeks for up to 4 cycles. Patients then receive AC IV every 3 weeks for up to 4 cycles. Patients then undergo surgery (lumpectomy or mastectomy).
cyclophosphamide: 600 mg/m2 IV
docetaxel: 100 mg/m2 IV
doxorubicin hydrochloride (Adriamycin): 60 mg/m2 IV</description>
          </group>
          <group group_id="O2">
            <title>Arm 1B Docetaxel + Bev Then AC + Bev</title>
            <description>Patients receive bevacizumab (bev) IV on day 1 and docetaxel every 3 weeks for up to 4 cycles. Patients then receive AC every 3 weeks for up to 4 cycles and 2 additional cycles of bevacizumab concurrent with the first 2 cycles of AC. Patients then undergo surgery as in Arm 1A. At least 4-6 weeks after surgery, patients receive adjuvant bevacizumab IV every 3 weeks for up to 10 cycles in the absence of disease progression or unacceptable toxicity.
bevacizumab: 15 mg/kg IV
cyclophosphamide: 600 mg/m2 IV
docetaxel: 100 mg/m2 IV
doxorubicin hydrochloride (Adriamycin): 60 mg/m2 IV</description>
          </group>
          <group group_id="O3">
            <title>Arm 2A: Docetaxel + Capecitabine Then AC</title>
            <description>Patients receive docetaxel as in Arm 1A and oral capecitabine (cape) twice daily on days 1-14 every 3 weeks for up to 4 cycles. Patients then receive AC as in Arm 1A. Patients then undergo surgery as in Arm 1A.
capecitabine: 825 mg/m2 orally
cyclophosphamide: 600 mg/m2 IV
docetaxel: 100 mg/m2 IV
doxorubicin hydrochloride (Adriamycin): 60 mg/m2 IV</description>
          </group>
          <group group_id="O4">
            <title>Arm 2B: Docetaxel + Cape + Bev Then AC + Bev</title>
            <description>Patients receive bevacizumab as in Arm 1B and docetaxel and capecitabine as in Arm III. Treatment repeats every 3 weeks for up to 4 cycles. Patients then receive AC every 3 weeks for up to 4 cycles and 2 additional cycles of bevacizumab concurrent with the first 2 cycles of AC. Patients then undergo surgery as in Arm 1B. At least 4-6 weeks after surgery, patients receive adjuvant bevacizumab as in Arm 1B.
bevacizumab: 15 mg/kg IV
capecitabine: 825 mg/m2 orally
cyclophosphamide: 600 mg/m2 IV
docetaxel: 100 mg/m2 IV
doxorubicin hydrochloride (Adriamycin): 60 mg/m2 IV</description>
          </group>
          <group group_id="O5">
            <title>Arm 3A: Docetaxel + Gem Then AC</title>
            <description>Patients receive docetaxel as in Arm 1A and gemcitabine hydrochloride IV on days 1 and 8 of each cycle every 3 weeks for up to 4 cycles. Patients then receive AC as in Arm 1A. Patients then undergo surgery as in Arm 1A.
cyclophosphamide: 600 mg/m2 IV
docetaxel: 100 mg/m2 IV
doxorubicin hydrochloride (Adriamycin): 60 mg/m2 IV
gemcitabine hydrochloride: 1000 mg/m2 IV</description>
          </group>
          <group group_id="O6">
            <title>Arm 3B: Docetaxel + Gem + Bev Then AC + Bev</title>
            <description>Patients receive docetaxel as in Arm 1A, gemcitabine hydrochloride as in Arm 3A, and bevacizumab as in Arm 1B. Patients then receive AC every 3 weeks for up to 4 cycles and 2 additional cycles of bevacizumab concurrent with the first 2 cycles of AC. Patients then undergo surgery as in Arm 1A. At least 4-6 weeks after surgery, patients receive adjuvant bevacizumab as in Arm 1B.
bevacizumab: 15 mg/kg IV
cyclophosphamide: 600 mg/m2 IV
docetaxel: 100 mg/m2 IV
doxorubicin hydrochloride (Adriamycin): 60 mg/m2 IV
gemcitabine hydrochloride: 1000 mg/m2 IV</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Overall Response (cOR) Following Docetaxel Alone, Docetaxel/Capecitabine, and Docetaxel/Gemcitabine Hydrochloride, With or Without Bevacizumab, as Assessed by Physical Exam at the Completion of the Docetaxel-based Portion of Chemotherapy</title>
          <description>Percentages of patients assessed as Clinical Complete Response or Clinical Partial Response according to RECIST.</description>
          <population>For Arm 1A there is no follow up data for 1 patient; Arm 1B no follow up data for 5 patients; Arm 2A no follow up data for 6 patients; Arm 2B no follow up data for 7 patients; Arm 3A no follow up data for 7 patients; Arm 3B no follow up data for 4 patients</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
                <count group_id="O2" value="194"/>
                <count group_id="O3" value="198"/>
                <count group_id="O4" value="194"/>
                <count group_id="O5" value="190"/>
                <count group_id="O6" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77" lower_limit="70.5" upper_limit="82.2"/>
                    <measurement group_id="O2" value="87.6" lower_limit="82.1" upper_limit="91.5"/>
                    <measurement group_id="O3" value="73.7" lower_limit="67" upper_limit="79.3"/>
                    <measurement group_id="O4" value="84" lower_limit="78.1" upper_limit="88.5"/>
                    <measurement group_id="O5" value="82.6" lower_limit="76.5" upper_limit="87.3"/>
                    <measurement group_id="O6" value="88" lower_limit="82.6" upper_limit="91.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Overall Response: cOR as Assessed by Physical Exam at the Completion of the Sequential Chemotherapy Regimens</title>
        <description>The percentage of patients assessed by physical exam as Clinical Complete Response or Clinical Partial Response according to RECIST.</description>
        <time_frame>Three to four weeks after the last chemotherapy dose on average 6 or 13 months</time_frame>
        <population>For Arm 1A there is no follow up data for 2 patients; Arm 1B no follow up data for 4 patients; Arm 2A no follow up data for 5 patients; Arm 2B no follow up data for 8 patients; Arm 3A no follow up data for 5 patients; Arm 3B no follow up data for 4 patients</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1A: Docetaxel Then AC</title>
            <description>Patients receive docetaxel IV on day 1 every 3 weeks for up to 4 cycles. Patients then receive AC IV every 3 weeks for up to 4 cycles. Patients then undergo surgery (lumpectomy or mastectomy).
cyclophosphamide: 600 mg/m2 IV
docetaxel: 100 mg/m2 IV
doxorubicin hydrochloride (Adriamycin): 60 mg/m2 IV</description>
          </group>
          <group group_id="O2">
            <title>Arm 1B Docetaxel + Bev Then AC + Bev</title>
            <description>Patients receive bevacizumab (bev) IV on day 1 and docetaxel every 3 weeks for up to 4 cycles. Patients then receive AC every 3 weeks for up to 4 cycles and 2 additional cycles of bevacizumab concurrent with the first 2 cycles of AC. Patients then undergo surgery as in Arm 1A. At least 4-6 weeks after surgery, patients receive adjuvant bevacizumab IV every 3 weeks for up to 10 cycles in the absence of disease progression or unacceptable toxicity.
bevacizumab: 15 mg/kg IV
cyclophosphamide: 600 mg/m2 IV
docetaxel: 100 mg/m2 IV
doxorubicin hydrochloride (Adriamycin): 60 mg/m2 IV</description>
          </group>
          <group group_id="O3">
            <title>Arm 2A: Docetaxel + Capecitabine Then AC</title>
            <description>Patients receive docetaxel as in Arm 1A and oral capecitabine (cape) twice daily on days 1-14 every 3 weeks for up to 4 cycles. Patients then receive AC as in Arm 1A. Patients then undergo surgery as in Arm 1A.
capecitabine: 825 mg/m2 orally
cyclophosphamide: 600 mg/m2 IV
docetaxel: 100 mg/m2 IV
doxorubicin hydrochloride (Adriamycin): 60 mg/m2 IV</description>
          </group>
          <group group_id="O4">
            <title>Arm 2B: Docetaxel + Cape + Bev Then AC + Bev</title>
            <description>Patients receive bevacizumab as in Arm 1B and docetaxel and capecitabine as in Arm III. Treatment repeats every 3 weeks for up to 4 cycles. Patients then receive AC every 3 weeks for up to 4 cycles and 2 additional cycles of bevacizumab concurrent with the first 2 cycles of AC. Patients then undergo surgery as in Arm 1B. At least 4-6 weeks after surgery, patients receive adjuvant bevacizumab as in Arm 1B.
bevacizumab: 15 mg/kg IV
capecitabine: 825 mg/m2 orally
cyclophosphamide: 600 mg/m2 IV
docetaxel: 100 mg/m2 IV
doxorubicin hydrochloride (Adriamycin): 60 mg/m2 IV</description>
          </group>
          <group group_id="O5">
            <title>Arm 3A: Docetaxel + Gem Then AC</title>
            <description>Patients receive docetaxel as in Arm 1A and gemcitabine hydrochloride IV on days 1 and 8 of each cycle every 3 weeks for up to 4 cycles. Patients then receive AC as in Arm 1A. Patients then undergo surgery as in Arm 1A.
cyclophosphamide: 600 mg/m2 IV
docetaxel: 100 mg/m2 IV
doxorubicin hydrochloride (Adriamycin): 60 mg/m2 IV
gemcitabine hydrochloride: 1000 mg/m2 IV</description>
          </group>
          <group group_id="O6">
            <title>Arm 3B: Docetaxel + Gem + Bev Then AC + Bev</title>
            <description>Patients receive docetaxel as in Arm 1A, gemcitabine hydrochloride as in Arm 3A, and bevacizumab as in Arm 1B. Patients then receive AC every 3 weeks for up to 4 cycles and 2 additional cycles of bevacizumab concurrent with the first 2 cycles of AC. Patients then undergo surgery as in Arm 1A. At least 4-6 weeks after surgery, patients receive adjuvant bevacizumab as in Arm 1B.
bevacizumab: 15 mg/kg IV
cyclophosphamide: 600 mg/m2 IV
docetaxel: 100 mg/m2 IV
doxorubicin hydrochloride (Adriamycin): 60 mg/m2 IV
gemcitabine hydrochloride: 1000 mg/m2 IV</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Overall Response: cOR as Assessed by Physical Exam at the Completion of the Sequential Chemotherapy Regimens</title>
          <description>The percentage of patients assessed by physical exam as Clinical Complete Response or Clinical Partial Response according to RECIST.</description>
          <population>For Arm 1A there is no follow up data for 2 patients; Arm 1B no follow up data for 4 patients; Arm 2A no follow up data for 5 patients; Arm 2B no follow up data for 8 patients; Arm 3A no follow up data for 5 patients; Arm 3B no follow up data for 4 patients</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="199"/>
                <count group_id="O2" value="195"/>
                <count group_id="O3" value="199"/>
                <count group_id="O4" value="193"/>
                <count group_id="O5" value="192"/>
                <count group_id="O6" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.9" lower_limit="73.6" upper_limit="84.8"/>
                    <measurement group_id="O2" value="87.7" lower_limit="82.2" upper_limit="91.6"/>
                    <measurement group_id="O3" value="75.4" lower_limit="68.8" upper_limit="80.8"/>
                    <measurement group_id="O4" value="90.7" lower_limit="85.6" upper_limit="94"/>
                    <measurement group_id="O5" value="83.3" lower_limit="77.3" upper_limit="87.9"/>
                    <measurement group_id="O6" value="80.5" lower_limit="74.3" upper_limit="85.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Complete Response (cCR) Following Docetaxel Alone, Docetaxel/Capecitabine, and Docetaxel/Gemcitabine Hydrochloride, With or Without Bevacizumab, as Assessed by Physical Exam at Completion of Therapy</title>
        <description>Percentages of patients assessed as Clinical Complete Response or Clinical Partial Response according to RECIST.</description>
        <time_frame>Assessed at cycle 5 of chemotherapy, on average at 15 weeks</time_frame>
        <population>For Arm 1A there is no follow up data for 2 patients; Arm 1B no follow up data for 4 patients; Arm 2A no follow up data for 5 patients; Arm 2B no follow up data for 8 patients; Arm 3A no follow up data for 5 patients; Arm 3B no follow up data for 4 patients</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1A: Docetaxel Then AC</title>
            <description>Patients receive docetaxel IV on day 1 every 3 weeks for up to 4 cycles. Patients then receive AC IV every 3 weeks for up to 4 cycles. Patients then undergo surgery (lumpectomy or mastectomy).
cyclophosphamide: 600 mg/m2 IV
docetaxel: 100 mg/m2 IV
doxorubicin hydrochloride (Adriamycin): 60 mg/m2 IV</description>
          </group>
          <group group_id="O2">
            <title>Arm 1B Docetaxel + Bev Then AC + Bev</title>
            <description>Patients receive bevacizumab (bev) IV on day 1 and docetaxel every 3 weeks for up to 4 cycles. Patients then receive AC every 3 weeks for up to 4 cycles and 2 additional cycles of bevacizumab concurrent with the first 2 cycles of AC. Patients then undergo surgery as in Arm 1A. At least 4-6 weeks after surgery, patients receive adjuvant bevacizumab IV every 3 weeks for up to 10 cycles in the absence of disease progression or unacceptable toxicity.
bevacizumab: 15 mg/kg IV
cyclophosphamide: 600 mg/m2 IV
docetaxel: 100 mg/m2 IV
doxorubicin hydrochloride (Adriamycin): 60 mg/m2 IV</description>
          </group>
          <group group_id="O3">
            <title>Arm 2A: Docetaxel + Capecitabine Then AC</title>
            <description>Patients receive docetaxel as in Arm 1A and oral capecitabine (cape) twice daily on days 1-14 every 3 weeks for up to 4 cycles. Patients then receive AC as in Arm 1A. Patients then undergo surgery as in Arm 1A.
capecitabine: 825 mg/m2 orally
cyclophosphamide: 600 mg/m2 IV
docetaxel: 100 mg/m2 IV
doxorubicin hydrochloride (Adriamycin): 60 mg/m2 IV</description>
          </group>
          <group group_id="O4">
            <title>Arm 2B: Docetaxel + Cape + Bev Then AC + Bev</title>
            <description>Patients receive bevacizumab as in Arm 1B and docetaxel and capecitabine as in Arm III. Treatment repeats every 3 weeks for up to 4 cycles. Patients then receive AC every 3 weeks for up to 4 cycles and 2 additional cycles of bevacizumab concurrent with the first 2 cycles of AC. Patients then undergo surgery as in Arm 1B. At least 4-6 weeks after surgery, patients receive adjuvant bevacizumab as in Arm 1B.
bevacizumab: 15 mg/kg IV
capecitabine: 825 mg/m2 orally
cyclophosphamide: 600 mg/m2 IV
docetaxel: 100 mg/m2 IV
doxorubicin hydrochloride (Adriamycin): 60 mg/m2 IV</description>
          </group>
          <group group_id="O5">
            <title>Arm 3A: Docetaxel + Gem Then AC</title>
            <description>Patients receive docetaxel as in Arm 1A and gemcitabine hydrochloride IV on days 1 and 8 of each cycle every 3 weeks for up to 4 cycles. Patients then receive AC as in Arm 1A. Patients then undergo surgery as in Arm 1A.
cyclophosphamide: 600 mg/m2 IV
docetaxel: 100 mg/m2 IV
doxorubicin hydrochloride (Adriamycin): 60 mg/m2 IV
gemcitabine hydrochloride: 1000 mg/m2 IV</description>
          </group>
          <group group_id="O6">
            <title>Arm 3B: Docetaxel + Gem + Bev Then AC + Bev</title>
            <description>Patients receive docetaxel as in Arm 1A, gemcitabine hydrochloride as in Arm 3A, and bevacizumab as in Arm 1B. Patients then receive AC every 3 weeks for up to 4 cycles and 2 additional cycles of bevacizumab concurrent with the first 2 cycles of AC. Patients then undergo surgery as in Arm 1A. At least 4-6 weeks after surgery, patients receive adjuvant bevacizumab as in Arm 1B.
bevacizumab: 15 mg/kg IV
cyclophosphamide: 600 mg/m2 IV
docetaxel: 100 mg/m2 IV
doxorubicin hydrochloride (Adriamycin): 60 mg/m2 IV
gemcitabine hydrochloride: 1000 mg/m2 IV</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Complete Response (cCR) Following Docetaxel Alone, Docetaxel/Capecitabine, and Docetaxel/Gemcitabine Hydrochloride, With or Without Bevacizumab, as Assessed by Physical Exam at Completion of Therapy</title>
          <description>Percentages of patients assessed as Clinical Complete Response or Clinical Partial Response according to RECIST.</description>
          <population>For Arm 1A there is no follow up data for 2 patients; Arm 1B no follow up data for 4 patients; Arm 2A no follow up data for 5 patients; Arm 2B no follow up data for 8 patients; Arm 3A no follow up data for 5 patients; Arm 3B no follow up data for 4 patients</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="199"/>
                <count group_id="O2" value="195"/>
                <count group_id="O3" value="199"/>
                <count group_id="O4" value="193"/>
                <count group_id="O5" value="192"/>
                <count group_id="O6" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30" lower_limit="23.8" upper_limit="36.4"/>
                    <measurement group_id="O2" value="43.3" lower_limit="36.3" upper_limit="50.1"/>
                    <measurement group_id="O3" value="29.8" lower_limit="23.6" upper_limit="36.2"/>
                    <measurement group_id="O4" value="34.5" lower_limit="27.9" upper_limit="41.2"/>
                    <measurement group_id="O5" value="37.9" lower_limit="31" upper_limit="44.7"/>
                    <measurement group_id="O6" value="42" lower_limit="35.1" upper_limit="48.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Complete Resonse: cCR as Assessed by Physical Exam at the Completion of the Sequential Chemotherapy Regimens</title>
        <description>The percentage of patients assessed by physical exam as Clinical Complete Response according to RECIST.</description>
        <time_frame>Three to four weeks after the last chemotherapy dose, on average at 6 or 13 months</time_frame>
        <population>For Arm 1A there is no follow up data for 2 patients; Arm 1B no follow up data for 4 patients; Arm 2A no follow up data for 5 patients; Arm 2B no follow up data for 8 patients; Arm 3A no follow up data for 5 patients; Arm 3B no follow up data for 4 patients</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1A: Docetaxel Then AC</title>
            <description>Patients receive docetaxel IV on day 1 every 3 weeks for up to 4 cycles. Patients then receive AC IV every 3 weeks for up to 4 cycles. Patients then undergo surgery (lumpectomy or mastectomy).
cyclophosphamide: 600 mg/m2 IV
docetaxel: 100 mg/m2 IV
doxorubicin hydrochloride (Adriamycin): 60 mg/m2 IV</description>
          </group>
          <group group_id="O2">
            <title>Arm 1B Docetaxel + Bev Then AC + Bev</title>
            <description>Patients receive bevacizumab (bev) IV on day 1 and docetaxel every 3 weeks for up to 4 cycles. Patients then receive AC every 3 weeks for up to 4 cycles and 2 additional cycles of bevacizumab concurrent with the first 2 cycles of AC. Patients then undergo surgery as in Arm 1A. At least 4-6 weeks after surgery, patients receive adjuvant bevacizumab IV every 3 weeks for up to 10 cycles in the absence of disease progression or unacceptable toxicity.
bevacizumab: 15 mg/kg IV
cyclophosphamide: 600 mg/m2 IV
docetaxel: 100 mg/m2 IV
doxorubicin hydrochloride (Adriamycin): 60 mg/m2 IV</description>
          </group>
          <group group_id="O3">
            <title>Arm 2A: Docetaxel + Capecitabine Then AC</title>
            <description>Patients receive docetaxel as in Arm 1A and oral capecitabine (cape) twice daily on days 1-14 every 3 weeks for up to 4 cycles. Patients then receive AC as in Arm 1A. Patients then undergo surgery as in Arm 1A.
capecitabine: 825 mg/m2 orally
cyclophosphamide: 600 mg/m2 IV
docetaxel: 100 mg/m2 IV
doxorubicin hydrochloride (Adriamycin): 60 mg/m2 IV</description>
          </group>
          <group group_id="O4">
            <title>Arm 2B: Docetaxel + Cape + Bev Then AC + Bev</title>
            <description>Patients receive bevacizumab as in Arm 1B and docetaxel and capecitabine as in Arm III. Treatment repeats every 3 weeks for up to 4 cycles. Patients then receive AC every 3 weeks for up to 4 cycles and 2 additional cycles of bevacizumab concurrent with the first 2 cycles of AC. Patients then undergo surgery as in Arm 1B. At least 4-6 weeks after surgery, patients receive adjuvant bevacizumab as in Arm 1B.
bevacizumab: 15 mg/kg IV
capecitabine: 825 mg/m2 orally
cyclophosphamide: 600 mg/m2 IV
docetaxel: 100 mg/m2 IV
doxorubicin hydrochloride (Adriamycin): 60 mg/m2 IV</description>
          </group>
          <group group_id="O5">
            <title>Arm 3A: Docetaxel + Gem Then AC</title>
            <description>Patients receive docetaxel as in Arm 1A and gemcitabine hydrochloride IV on days 1 and 8 of each cycle every 3 weeks for up to 4 cycles. Patients then receive AC as in Arm 1A. Patients then undergo surgery as in Arm 1A.
cyclophosphamide: 600 mg/m2 IV
docetaxel: 100 mg/m2 IV
doxorubicin hydrochloride (Adriamycin): 60 mg/m2 IV
gemcitabine hydrochloride: 1000 mg/m2 IV</description>
          </group>
          <group group_id="O6">
            <title>Arm 3B: Docetaxel + Gem + Bev Then AC + Bev</title>
            <description>Patients receive docetaxel as in Arm 1A, gemcitabine hydrochloride as in Arm 3A, and bevacizumab as in Arm 1B. Patients then receive AC every 3 weeks for up to 4 cycles and 2 additional cycles of bevacizumab concurrent with the first 2 cycles of AC. Patients then undergo surgery as in Arm 1A. At least 4-6 weeks after surgery, patients receive adjuvant bevacizumab as in Arm 1B.
bevacizumab: 15 mg/kg IV
cyclophosphamide: 600 mg/m2 IV
docetaxel: 100 mg/m2 IV
doxorubicin hydrochloride (Adriamycin): 60 mg/m2 IV
gemcitabine hydrochloride: 1000 mg/m2 IV</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Complete Resonse: cCR as Assessed by Physical Exam at the Completion of the Sequential Chemotherapy Regimens</title>
          <description>The percentage of patients assessed by physical exam as Clinical Complete Response according to RECIST.</description>
          <population>For Arm 1A there is no follow up data for 2 patients; Arm 1B no follow up data for 4 patients; Arm 2A no follow up data for 5 patients; Arm 2B no follow up data for 8 patients; Arm 3A no follow up data for 5 patients; Arm 3B no follow up data for 4 patients</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="199"/>
                <count group_id="O2" value="195"/>
                <count group_id="O3" value="199"/>
                <count group_id="O4" value="193"/>
                <count group_id="O5" value="192"/>
                <count group_id="O6" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.3" lower_limit="45.1" upper_limit="58.9"/>
                    <measurement group_id="O2" value="64.6" lower_limit="57.5" upper_limit="70.9"/>
                    <measurement group_id="O3" value="51.3" lower_limit="44.1" upper_limit="57.9"/>
                    <measurement group_id="O4" value="59.1" lower_limit="51.8" upper_limit="65.6"/>
                    <measurement group_id="O5" value="52.6" lower_limit="45.3" upper_limit="59.4"/>
                    <measurement group_id="O6" value="60" lower_limit="52.9" upper_limit="66.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Cardiac Events</title>
        <time_frame>After each cycle, 3-5 weeks postoperative, 9 and 12 months from study entry, every 6 month years 2-5, and annually years 6-10, for postoperative bevacizumab patients, every 6 weeks during postoperative therapy and at 18 months following study entry.</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Surgical Complication</title>
        <description>Number of patients with Grade 4 or above surgery-related toxicities</description>
        <time_frame>24 months after study entry</time_frame>
        <population>For Arm 1A there is no follow up data for 8 patients; Arm 1B no follow up data for 8 patients; Arm 2A no follow up data for 6 patients; Arm 2B no follow up data for 12 patients; Arm 3A no follow up data for 11 patients; Arm 3B no follow up data for 7 patients</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1A: Docetaxel Then AC</title>
            <description>Patients receive docetaxel IV on day 1 every 3 weeks for up to 4 cycles. Patients then receive AC IV every 3 weeks for up to 4 cycles. Patients then undergo surgery (lumpectomy or mastectomy).
cyclophosphamide: 600 mg/m2 IV
docetaxel: 100 mg/m2 IV
doxorubicin hydrochloride (Adriamycin): 60 mg/m2 IV</description>
          </group>
          <group group_id="O2">
            <title>Arm 1B Docetaxel + Bev Then AC + Bev</title>
            <description>Patients receive bevacizumab (bev) IV on day 1 and docetaxel every 3 weeks for up to 4 cycles. Patients then receive AC every 3 weeks for up to 4 cycles and 2 additional cycles of bevacizumab concurrent with the first 2 cycles of AC. Patients then undergo surgery as in Arm 1A. At least 4-6 weeks after surgery, patients receive adjuvant bevacizumab IV every 3 weeks for up to 10 cycles in the absence of disease progression or unacceptable toxicity.
bevacizumab: 15 mg/kg IV
cyclophosphamide: 600 mg/m2 IV
docetaxel: 100 mg/m2 IV
doxorubicin hydrochloride (Adriamycin): 60 mg/m2 IV</description>
          </group>
          <group group_id="O3">
            <title>Arm 2A: Docetaxel + Capecitabine Then AC</title>
            <description>Patients receive docetaxel as in Arm 1A and oral capecitabine (cape) twice daily on days 1-14 every 3 weeks for up to 4 cycles. Patients then receive AC as in Arm 1A. Patients then undergo surgery as in Arm 1A.
capecitabine: 825 mg/m2 orally
cyclophosphamide: 600 mg/m2 IV
docetaxel: 100 mg/m2 IV
doxorubicin hydrochloride (Adriamycin): 60 mg/m2 IV</description>
          </group>
          <group group_id="O4">
            <title>Arm 2B: Docetaxel + Cape + Bev Then AC + Bev</title>
            <description>Patients receive bevacizumab as in Arm 1B and docetaxel and capecitabine as in Arm III. Treatment repeats every 3 weeks for up to 4 cycles. Patients then receive AC every 3 weeks for up to 4 cycles and 2 additional cycles of bevacizumab concurrent with the first 2 cycles of AC. Patients then undergo surgery as in Arm 1B. At least 4-6 weeks after surgery, patients receive adjuvant bevacizumab as in Arm 1B.
bevacizumab: 15 mg/kg IV
capecitabine: 825 mg/m2 orally
cyclophosphamide: 600 mg/m2 IV
docetaxel: 100 mg/m2 IV
doxorubicin hydrochloride (Adriamycin): 60 mg/m2 IV</description>
          </group>
          <group group_id="O5">
            <title>Arm 3A: Docetaxel + Gem Then AC</title>
            <description>Patients receive docetaxel as in Arm 1A and gemcitabine hydrochloride IV on days 1 and 8 of each cycle every 3 weeks for up to 4 cycles. Patients then receive AC as in Arm 1A. Patients then undergo surgery as in Arm 1A.
cyclophosphamide: 600 mg/m2 IV
docetaxel: 100 mg/m2 IV
doxorubicin hydrochloride (Adriamycin): 60 mg/m2 IV
gemcitabine hydrochloride: 1000 mg/m2 IV</description>
          </group>
          <group group_id="O6">
            <title>Arm 3B: Docetaxel + Gem + Bev Then AC + Bev</title>
            <description>Patients receive docetaxel as in Arm 1A, gemcitabine hydrochloride as in Arm 3A, and bevacizumab as in Arm 1B. Patients then receive AC every 3 weeks for up to 4 cycles and 2 additional cycles of bevacizumab concurrent with the first 2 cycles of AC. Patients then undergo surgery as in Arm 1A. At least 4-6 weeks after surgery, patients receive adjuvant bevacizumab as in Arm 1B.
bevacizumab: 15 mg/kg IV
cyclophosphamide: 600 mg/m2 IV
docetaxel: 100 mg/m2 IV
doxorubicin hydrochloride (Adriamycin): 60 mg/m2 IV
gemcitabine hydrochloride: 1000 mg/m2 IV</description>
          </group>
        </group_list>
        <measure>
          <title>Surgical Complication</title>
          <description>Number of patients with Grade 4 or above surgery-related toxicities</description>
          <population>For Arm 1A there is no follow up data for 8 patients; Arm 1B no follow up data for 8 patients; Arm 2A no follow up data for 6 patients; Arm 2B no follow up data for 12 patients; Arm 3A no follow up data for 11 patients; Arm 3B no follow up data for 7 patients</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="193"/>
                <count group_id="O2" value="191"/>
                <count group_id="O3" value="198"/>
                <count group_id="O4" value="189"/>
                <count group_id="O5" value="186"/>
                <count group_id="O6" value="197"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Toxicities Including Events Other Than Congestive Heart Failure, of Chemotherapy Alone, Bevacizumab With Chemotherapy, and Bevacizumab Alone</title>
        <description>The number of patients who experienced Grade 1 or above Adverse Events. Referring to the Adverse Events tables for specifics.</description>
        <time_frame>24 months after study entry</time_frame>
        <population>For Arm 1A there is no followup data for 2 patients; for Arm 2A there is no followup data for 1 patient; for Arm 3A there is no followup data for 3 patients; for Arm 1B there is no followup data for 3 patients; for Arm 2B there is no followup data for 5 patients; and for Arm 3B there is no followup data for 2 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1A: Docetaxel Then AC</title>
            <description>Patients receive docetaxel IV on day 1 every 3 weeks for up to 4 cycles. Patients then receive AC IV every 3 weeks for up to 4 cycles. Patients then undergo surgery (lumpectomy or mastectomy).
cyclophosphamide: 600 mg/m2 IV
docetaxel: 100 mg/m2 IV
doxorubicin hydrochloride (Adriamycin): 60 mg/m2 IV</description>
          </group>
          <group group_id="O2">
            <title>Arm 1B Docetaxel + Bev Then AC + Bev</title>
            <description>Patients receive bevacizumab (bev) IV on day 1 and docetaxel every 3 weeks for up to 4 cycles. Patients then receive AC every 3 weeks for up to 4 cycles and 2 additional cycles of bevacizumab concurrent with the first 2 cycles of AC. Patients then undergo surgery as in Arm 1A. At least 4-6 weeks after surgery, patients receive adjuvant bevacizumab IV every 3 weeks for up to 10 cycles in the absence of disease progression or unacceptable toxicity.
bevacizumab: 15 mg/kg IV
cyclophosphamide: 600 mg/m2 IV
docetaxel: 100 mg/m2 IV
doxorubicin hydrochloride (Adriamycin): 60 mg/m2 IV</description>
          </group>
          <group group_id="O3">
            <title>Arm 2A: Docetaxel + Capecitabine Then AC</title>
            <description>Patients receive docetaxel as in Arm 1A and oral capecitabine (cape) twice daily on days 1-14 every 3 weeks for up to 4 cycles. Patients then receive AC as in Arm 1A. Patients then undergo surgery as in Arm 1A.
capecitabine: 825 mg/m2 orally
cyclophosphamide: 600 mg/m2 IV
docetaxel: 100 mg/m2 IV
doxorubicin hydrochloride (Adriamycin): 60 mg/m2 IV</description>
          </group>
          <group group_id="O4">
            <title>Arm 2B: Docetaxel + Cape + Bev Then AC + Bev</title>
            <description>Patients receive bevacizumab as in Arm 1B and docetaxel and capecitabine as in Arm III. Treatment repeats every 3 weeks for up to 4 cycles. Patients then receive AC every 3 weeks for up to 4 cycles and 2 additional cycles of bevacizumab concurrent with the first 2 cycles of AC. Patients then undergo surgery as in Arm 1B. At least 4-6 weeks after surgery, patients receive adjuvant bevacizumab as in Arm 1B.
bevacizumab: 15 mg/kg IV
capecitabine: 825 mg/m2 orally
cyclophosphamide: 600 mg/m2 IV
docetaxel: 100 mg/m2 IV
doxorubicin hydrochloride (Adriamycin): 60 mg/m2 IV</description>
          </group>
          <group group_id="O5">
            <title>Arm 3A: Docetaxel + Gem Then AC</title>
            <description>Patients receive docetaxel as in Arm 1A and gemcitabine hydrochloride IV on days 1 and 8 of each cycle every 3 weeks for up to 4 cycles. Patients then receive AC as in Arm 1A. Patients then undergo surgery as in Arm 1A.
cyclophosphamide: 600 mg/m2 IV
docetaxel: 100 mg/m2 IV
doxorubicin hydrochloride (Adriamycin): 60 mg/m2 IV
gemcitabine hydrochloride: 1000 mg/m2 IV</description>
          </group>
          <group group_id="O6">
            <title>Arm 3B: Docetaxel + Gem + Bev Then AC + Bev</title>
            <description>Patients receive docetaxel as in Arm 1A, gemcitabine hydrochloride as in Arm 3A, and bevacizumab as in Arm 1B. Patients then receive AC every 3 weeks for up to 4 cycles and 2 additional cycles of bevacizumab concurrent with the first 2 cycles of AC. Patients then undergo surgery as in Arm 1A. At least 4-6 weeks after surgery, patients receive adjuvant bevacizumab as in Arm 1B.
bevacizumab: 15 mg/kg IV
cyclophosphamide: 600 mg/m2 IV
docetaxel: 100 mg/m2 IV
doxorubicin hydrochloride (Adriamycin): 60 mg/m2 IV
gemcitabine hydrochloride: 1000 mg/m2 IV</description>
          </group>
        </group_list>
        <measure>
          <title>Toxicities Including Events Other Than Congestive Heart Failure, of Chemotherapy Alone, Bevacizumab With Chemotherapy, and Bevacizumab Alone</title>
          <description>The number of patients who experienced Grade 1 or above Adverse Events. Referring to the Adverse Events tables for specifics.</description>
          <population>For Arm 1A there is no followup data for 2 patients; for Arm 2A there is no followup data for 1 patient; for Arm 3A there is no followup data for 3 patients; for Arm 1B there is no followup data for 3 patients; for Arm 2B there is no followup data for 5 patients; and for Arm 3B there is no followup data for 2 patients.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="199"/>
                <count group_id="O2" value="196"/>
                <count group_id="O3" value="203"/>
                <count group_id="O4" value="196"/>
                <count group_id="O5" value="194"/>
                <count group_id="O6" value="202"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="180"/>
                    <measurement group_id="O2" value="157"/>
                    <measurement group_id="O3" value="172"/>
                    <measurement group_id="O4" value="185"/>
                    <measurement group_id="O5" value="158"/>
                    <measurement group_id="O6" value="185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease-free Survival (DFS)</title>
        <description>Percentage of patients free from local recurrence following mastectomy, local recurrence in the ipsilateral breast following lumpectomy, regional recurrence, distant recurrence, contralateral breast cancer, second primary cancer after 5 years.</description>
        <time_frame>Measured through 5 years after study enrollment</time_frame>
        <population>For Arm 1A there is no follow up data for 2 patients; Arm 1B no follow up data for 4 patients; Arm 2B no follow up data for 6 patients; Arm 3A no follow up data for 7 patients; Arm 3B no follow up data for 3 patients</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1A: Docetaxel Then AC</title>
            <description>Patients receive docetaxel IV on day 1 every 3 weeks for up to 4 cycles. Patients then receive AC IV every 3 weeks for up to 4 cycles. Patients then undergo surgery (lumpectomy or mastectomy).
cyclophosphamide: 600 mg/m2 IV
docetaxel: 100 mg/m2 IV
doxorubicin hydrochloride (Adriamycin): 60 mg/m2 IV</description>
          </group>
          <group group_id="O2">
            <title>Arm 1B Docetaxel + Bev Then AC + Bev</title>
            <description>Patients receive bevacizumab (bev) IV on day 1 and docetaxel every 3 weeks for up to 4 cycles. Patients then receive AC every 3 weeks for up to 4 cycles and 2 additional cycles of bevacizumab concurrent with the first 2 cycles of AC. Patients then undergo surgery as in Arm 1A. At least 4-6 weeks after surgery, patients receive adjuvant bevacizumab IV every 3 weeks for up to 10 cycles in the absence of disease progression or unacceptable toxicity.
bevacizumab: 15 mg/kg IV
cyclophosphamide: 600 mg/m2 IV
docetaxel: 100 mg/m2 IV
doxorubicin hydrochloride (Adriamycin): 60 mg/m2 IV</description>
          </group>
          <group group_id="O3">
            <title>Arm 2A: Docetaxel + Capecitabine Then AC</title>
            <description>Patients receive docetaxel as in Arm 1A and oral capecitabine (cape) twice daily on days 1-14 every 3 weeks for up to 4 cycles. Patients then receive AC as in Arm 1A. Patients then undergo surgery as in Arm 1A.
capecitabine: 825 mg/m2 orally
cyclophosphamide: 600 mg/m2 IV
docetaxel: 100 mg/m2 IV
doxorubicin hydrochloride (Adriamycin): 60 mg/m2 IV</description>
          </group>
          <group group_id="O4">
            <title>Arm 2B: Docetaxel + Cape + Bev Then AC + Bev</title>
            <description>Patients receive bevacizumab as in Arm 1B and docetaxel and capecitabine as in Arm III. Treatment repeats every 3 weeks for up to 4 cycles. Patients then receive AC every 3 weeks for up to 4 cycles and 2 additional cycles of bevacizumab concurrent with the first 2 cycles of AC. Patients then undergo surgery as in Arm 1B. At least 4-6 weeks after surgery, patients receive adjuvant bevacizumab as in Arm 1B.
bevacizumab: 15 mg/kg IV
capecitabine: 825 mg/m2 orally
cyclophosphamide: 600 mg/m2 IV
docetaxel: 100 mg/m2 IV
doxorubicin hydrochloride (Adriamycin): 60 mg/m2 IV</description>
          </group>
          <group group_id="O5">
            <title>Arm 3A: Docetaxel + Gem Then AC</title>
            <description>Patients receive docetaxel as in Arm 1A and gemcitabine hydrochloride IV on days 1 and 8 of each cycle every 3 weeks for up to 4 cycles. Patients then receive AC as in Arm 1A. Patients then undergo surgery as in Arm 1A.
cyclophosphamide: 600 mg/m2 IV
docetaxel: 100 mg/m2 IV
doxorubicin hydrochloride (Adriamycin): 60 mg/m2 IV
gemcitabine hydrochloride: 1000 mg/m2 IV</description>
          </group>
          <group group_id="O6">
            <title>Arm 3B: Docetaxel + Gem + Bev Then AC + Bev</title>
            <description>Patients receive docetaxel as in Arm 1A, gemcitabine hydrochloride as in Arm 3A, and bevacizumab as in Arm 1B. Patients then receive AC every 3 weeks for up to 4 cycles and 2 additional cycles of bevacizumab concurrent with the first 2 cycles of AC. Patients then undergo surgery as in Arm 1A. At least 4-6 weeks after surgery, patients receive adjuvant bevacizumab as in Arm 1B.
bevacizumab: 15 mg/kg IV
cyclophosphamide: 600 mg/m2 IV
docetaxel: 100 mg/m2 IV
doxorubicin hydrochloride (Adriamycin): 60 mg/m2 IV
gemcitabine hydrochloride: 1000 mg/m2 IV</description>
          </group>
        </group_list>
        <measure>
          <title>Disease-free Survival (DFS)</title>
          <description>Percentage of patients free from local recurrence following mastectomy, local recurrence in the ipsilateral breast following lumpectomy, regional recurrence, distant recurrence, contralateral breast cancer, second primary cancer after 5 years.</description>
          <population>For Arm 1A there is no follow up data for 2 patients; Arm 1B no follow up data for 4 patients; Arm 2B no follow up data for 6 patients; Arm 3A no follow up data for 7 patients; Arm 3B no follow up data for 3 patients</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="199"/>
                <count group_id="O2" value="195"/>
                <count group_id="O3" value="204"/>
                <count group_id="O4" value="195"/>
                <count group_id="O5" value="190"/>
                <count group_id="O6" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.4" lower_limit="66.2" upper_limit="79.3"/>
                    <measurement group_id="O2" value="72.2" lower_limit="65.1" upper_limit="78.1"/>
                    <measurement group_id="O3" value="68.5" lower_limit="61" upper_limit="74.9"/>
                    <measurement group_id="O4" value="77.1" lower_limit="69.7" upper_limit="82.9"/>
                    <measurement group_id="O5" value="72.9" lower_limit="65.3" upper_limit="79.1"/>
                    <measurement group_id="O6" value="74.8" lower_limit="66.1" upper_limit="81.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Participants at Risk includes any patient who submitted an AE form.</desc>
      <group_list>
        <group group_id="E1">
          <title>Docetaxel Then AC</title>
          <description>Docetaxel then AC</description>
        </group>
        <group group_id="E2">
          <title>Docetaxel + Bev Then AC + Bev</title>
          <description>Docetaxel + Bev then AC + Bev</description>
        </group>
        <group group_id="E3">
          <title>Docetaxel + Capecitabine Then AC</title>
          <description>Docetaxel + Capecitabine then AC</description>
        </group>
        <group group_id="E4">
          <title>Docetaxel + Cape + Bev Then AC + Bev</title>
          <description>Docetaxel + Cape + Bev then AC + Bev</description>
        </group>
        <group group_id="E5">
          <title>Docetaxel + Gem Then AC</title>
          <description>Docetaxel + Gem then AC</description>
        </group>
        <group group_id="E6">
          <title>Docetaxel + Gem + Bev Then AC + Bev</title>
          <description>Docetaxel + Gem + Bev then AC + Bev</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE v4.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="30" subjects_at_risk="196"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="194"/>
                <counts group_id="E6" subjects_affected="15" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Blood and lymphatic system disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Heart failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Left ventricular systolic dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="196"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Colonic hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Colonic perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Small intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Anal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Sudden death NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Endocarditis infective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Infections and infestations - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Abdominal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="196"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Cardiac troponin I increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Investigations - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="196"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="194"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myositis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Leukemia secondary to oncology chemotherapy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Treatment related secondary malignancy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Nervous system disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Uterine hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="196"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Pleural hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Stevens-Johnson syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Thromboembolic event</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="196"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Vascular disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Visceral arterial ischemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE v4.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="118" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="150" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="168" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="182" subjects_at_risk="196"/>
                <counts group_id="E5" subjects_affected="150" subjects_at_risk="194"/>
                <counts group_id="E6" subjects_affected="178" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="196"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="194"/>
                <counts group_id="E6" subjects_affected="19" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="52" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="43" subjects_at_risk="196"/>
                <counts group_id="E5" subjects_affected="41" subjects_at_risk="194"/>
                <counts group_id="E6" subjects_affected="43" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="56" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="83" subjects_at_risk="196"/>
                <counts group_id="E5" subjects_affected="38" subjects_at_risk="194"/>
                <counts group_id="E6" subjects_affected="58" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="196"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="194"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="196"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="194"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="196"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="194"/>
                <counts group_id="E6" subjects_affected="22" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and infestations - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="196"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="194"/>
                <counts group_id="E6" subjects_affected="20" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased (ALT/SGPT)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="196"/>
                <counts group_id="E5" subjects_affected="26" subjects_at_risk="194"/>
                <counts group_id="E6" subjects_affected="35" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased (AST/SGOT)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="196"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="194"/>
                <counts group_id="E6" subjects_affected="27" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="42" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="37" subjects_at_risk="196"/>
                <counts group_id="E5" subjects_affected="64" subjects_at_risk="194"/>
                <counts group_id="E6" subjects_affected="70" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="196"/>
                <counts group_id="E5" subjects_affected="22" subjects_at_risk="194"/>
                <counts group_id="E6" subjects_affected="16" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="196"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="194"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="196"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="194"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="196"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="194"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="196"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="194"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="196"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="194"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="40" subjects_at_risk="196"/>
                <counts group_id="E5" subjects_affected="19" subjects_at_risk="194"/>
                <counts group_id="E6" subjects_affected="21" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="196"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="194"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="196"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="194"/>
                <counts group_id="E6" subjects_affected="14" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="29" subjects_at_risk="196"/>
                <counts group_id="E5" subjects_affected="33" subjects_at_risk="194"/>
                <counts group_id="E6" subjects_affected="38" subjects_at_risk="202"/>
              </event>
              <event>
                <sub_title>Palmar-plantar erythrodysesthesia syndrome</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="92" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="110" subjects_at_risk="196"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="194"/>
                <counts group_id="E6" subjects_affected="14" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="199"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="196"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="203"/>
                <counts group_id="E4" subjects_affected="43" subjects_at_risk="196"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="194"/>
                <counts group_id="E6" subjects_affected="49" subjects_at_risk="202"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director, Department of Regulatory Affairs</name_or_title>
      <organization>NSABP Foundation, Inc</organization>
      <phone>412-339-5300</phone>
      <email>regulatory@nsabp.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

